Enhanced immunomodulatory applications of nucleic acid encapsulating liposomes by Erikçi, Erdem
ENHANCED IMMUNOMODULATORY APPLICATIONS OF NUCLEIC
ACID ENCAPSULATING LIPOSOMES
A THESIS SUBMITTED TO
THE DEPARTMENT OF MOLECULAR BIOLOGY AND GENETICS
AND THE INSTITUTE OF ENGINEERING AND SCIENCE OF
BILKENT UNIVERSITY
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR
THE DEGREE OF MASTER OF SCIENCE
BY
ERDEM ERİKÇİ
AUGUST 2009
ii
I certify that I have read this thesis and that in my opinion it is fully adequate, in
scope and in quality, as a thesis for the degree of Master of Science.
Assoc. Prof. Dr. İhsan Gürsel
I certify that I have read this thesis and that in my opinion it is fully adequate, in
scope and in quality, as a thesis for the degree of Master of Science.
Assist. Prof. Dr. Kamil Can Akçalı
I certify that I have read this thesis and that in my opinion it is fully adequate, in
scope and in quality, as a thesis for the degree of Master of Science.
  Assoc. Prof. Dr. Cansın Saçkesen
Approved for the Institute of Engineering and Science
Director of Institute of Engineering and Science
Prof. Dr. Mehmet Baray
iii
ABSTRACT
ENHANCED IMMUNOMODULATORY APPLICATIONS OF NUCLEIC
ACID ENCAPSULATING LIPOSOMES
Erdem Erikçi
M.Sc. in Molecular Biology and Genetics
Supervisor: Assoc. Prof. Dr. İhsan Gürsel
August 2009
Recent studies have demonstrated that innate immune system has great ability to
discriminate self from non-self through the action of innate immune receptors. The most
extensively studied innate immune receptor family is the Toll-like receptors (TLRs).
Endosomal/intracellular TLR3, TLR7/8 and TLR9 recognize dsRNA, ssRNA and unmethylated
CpG DNA respectively. Upon activation following recognition of nucleic acids by endosomal
TLRs, B cells secrete IL6, dendritic cells and macrophages secrete type I IFNs, IL12 and NK
cells secrete IFNγ which yields Th1 type immune response. Modulating the immune response to
mount such an immune response by TLR ligands are harnessed in medical applications such as
anticancer, antiviral, antibacterial therapies, anti-allergen, as vaccine adjuvant and as
immunoprotective agents.
Promising clinical applications of TLR ligand nucleic acids are hampered due to their
premature in vivo digestion by endonucleases and rapid clearance via serum protein absorption
leading to limited stability and bioavailability. A powerful tool to overcome this problem can be
achieved by encapsulating TLR ligands within liposomes, which increase in vivo stability as well
as augment targeting and internalization to relevant innate immune cells.
In this study we aimed to establish the most immunostimulatory liposome type
encapsulating or coencapsulating CpG ODN and pIC. Five different liposomes possessing
different physicochemical properties were prepared and their immunostimulatory potential when
nucleic acid TLRs are loaded, were assessed. Following stimulation of splenocytes with
combinations of these liposome types we have observed that neutral, anionic and stealth
liposome encapsulating D-ODN, led to a dose dependent significantly higher IFNγ production
over free counterpart. Stealth liposome encapsulating pIC induced both IL6 and IFNγ 10 and 250
fold respectively over free pIC. Neutral and anionic liposome coencapsulating D-ODN with pIC
were very strong type 1 IFN as well as Th1 cytokine inducers both in vitro and ex vivo. Then, we
immunized B6 mice with anionic liposome coencapsulating D-ODN and OVA to establish the
immuno-adjuvant properties of liposome formulations in vivo. We assessed primary and
secondary anti-OVA IgG subclass responses of mice. Results strongly implicated that even after
primary immunization, we could obtain significantly higher anti-OVA IgG and IgG2a response
over OVA mixed D-ODN group. After booster injection, 22 fold more IgG, 26 fold more IgG1
and 13 fold more IgG2a were obtained compared to free group. Our findings demonstrated that
when simultaneous delivery of adjuvant (D-ODN) and antigen (OVA) within a proper depot
system is given to a host, very potent antigen specific immunity is achieved. This knowledge will
pave the way to design of novel effective vaccine adjuvants.
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ÖZET
NÜKLEİK ASİT İÇEREN LİPOZOMLARIN GELİŞMİŞ
İMMÜNMODÜLATÖR UYGULAMALARI
Erdem Erikçi
Moleküler Biyoloji ve Genetik Yüksek Lisans
Danışman: Doç. Dr. İhsan Gürsel
Ağustos 2009
Son çalışmalar, bağışıklık sisteminin doğal bağışıklık sistemi reseptörleri yoluyla
kendinden olan ve olmayan varlıkların ayrılmasında çok başarılı olduğu göstermiştir. Doğal
bağışıklık sistemi reseptörleri arasından üzerinde en çok çalışılan Toll-benzeri reseptörlerdir
(TLR). Endozomlarda bulunan TLR3, TLR7/8 ve TLR9 sırasıyla dsRNA, ssRNA ve
metillenmemiş CpG DNA’yı tanır. TLR tarafından algılanma sonucu aktifleşen B hücreleri IL6,
dendritic hücreler ve makrofajlar Tip I IFN ve IL12,NK hücreleri ise IFNγ salgılar ki bu
sitokinler Th1 tipi bağışıklık tepkisi verilmesini sağlar. TLR ligantlarını kullanarak bağışıklık
sistemine Th1 tipi tepki verdirmenin kansere ve alerjiye karşı tedavilerde, aşı adjuvanı şeklinde
veya viral ve bakteriyel enfeksiyonlara karşı koruyucu ajan olarak uygulamaları olabilir.
TLR ligantı nükleik asitlerin etkin uygulamaları, malzemenin sağlamlığını ve etkinliğini
etkileyen kan içinde hızla parçalanması ve serum proteinleri tarafından adsorbe edilmesi
nedeniyle sekteye uğramaktadır. Bu problem TLR ligantlarının in vivo’da yapısını koruyan,
doğal bağışıklık hücrelerine hedeflenmesi ve hücre içine alınmasını arttıran lipozomlara
enkapsüle edilmesi ile çözülebilinir.
Biz bu çalışmada en güçlü bağışıklık tepkisi verdiren pIC ve CpG ODN enkapsüle eden
lipozomun belirlenmesine çalışıldı. Farklı fizikokimyasal özelliklere sahip TLR ligantı nükleik
asit içeren lipozomlar hazırlandı ve immün uyarıcı potansiyelleri tayin edildi. Dalak hücrelerinin
lipozom kombinasyonları ile uyarılması sonucunda yüksüz, negatif yüklü ve stealth lipozomun
içine enkapsüle D-ODN’in,  serbest  haline göre IFNγ salgılanmasında doza bağlı güçlü bir artış
görüldü. pIC içeren stealth lipozomun serbest pIC’ye göre IL6 salgılanmasını 10 kat, IFNγ’yı ise
250 kat arttırdığı tespit edildi. D-ODN ve pIC’yi beraber enkapsüle eden yüksüz ve eksi yüklü
lipozomun tip I IFN ve Th1 tipi sitokin salgılanmasını in vitro ve in vivo’da güçlü bir şekilde
teşvik ettiği gözlemlendi. Daha sonra D-ODN ve OVA antijenini beraber enkapsüle eden eksi
yüklü lipozomun immün-adjuvant özelliğini in vivo’da göstermek için B6 fareleri lipozom
formülasyonları ile aşılandı. Farelerin birincil ve ikincil aşılama sonucu verdikleri anti-OVA IgG
alt sınıflarının tepkilerini tayin edildi. İlk aşılamadan sonra bile D-ODN’in ve OVA’nın serbest
halde aşılandığı gruba göre IgG ve IgG2a titrasyonunda kayda değer artış gözlendi. İkincil
aşılamadan sonra ise IgG miktarında 22 kat, IgG1 miktarında 26 ve IgG2a miktarında 13 kat artış
tespit edildi. Bulgularımız, adjuvanın (D-ODN) ve antijenin (OVA) uygun bir depo sistemi ile
konağa verilmesi sonucu çok etkili antijene özel immün tepkisi elde edildiğini gösteriyor. Bu
bilgi yeni ve etkili aşı yardımcıları geliştirilmesinin önünü açacaktır.
Anahtar kelimeler: TLR, CpG DNA, lipozom, aşılama, sitokin, IgG
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11. INTRODUCTION
The most effective way to fight against infectious diseases is vaccination.
Nevertheless vaccines are not available for numerous infectious diseases such as malaria and
HIV/AIDS or effectiveness of available vaccines are controversial. For instance BCG
vaccine was developed in early twentieth century by French scientists Albert Calmette and
Camille Guerin consisting of an attenuated strain of Mycobacterium bovis. It has been used
more than 70 years and its efficacy is somewhat controversial. Although meta-analysis of
literature yields theoretical efficacy rate of 50% no matter the age of vaccinated individual
(Brewer 2000), it is suggested that BCG fails to protect against pulmonary TB in adults,
which is the primary source of dissemination. (Kaufmann 2000)
Safety profile of vaccine that will substitute BCG is very important, because this
vaccine will obviously be applied to HIV positive patients. The disadvantage of attenuated
vaccines is that the attenuated strains have risk to develop disease in immunodeficient
patients. For instance, WHO does not suggest application of BCG vaccine to HIV-positive
children (Reece et al. 2008).  Subunit vaccines are more favorable at this point.
Subunit vaccines are composed of antigen specific for the pathogen, which the
vaccine is designed against for. The antigen would be protein component of capsids of a
virus or secreted protein of bacteria. However antigens are not immunogenic. Therefore
subunit vaccines contain adjuvant (e.g. aluminum hydroxide). According to the nature of
adjuvants,  the  response  of  immune  system  against  antigens  differs.  That’s  why,  while
designing an effective vaccine against an infectious disease, the nature and infecting strategy
of the pathogen should be considered. The adjuvant included in vaccine must trigger the
correct immune response, which will be effective against the disease.
To eradicate the infectious diseases and stop infectious disease related deaths, or at
least reduce the number of deaths to the level of interpretations at 2030, effective and
attainable vaccines against every infectious disease should be discovered. Formulating a
strong vaccine adjuvant is the first step of vaccine discovery process. In this project we tried
to reveal novel and effective vaccine adjuvant. The formulas we are offering contains
synthetic form of unmethylated DNA containing cytosine-phosphate-guanine (CpG) motif,
which is called CpG oligodeoxynucleotide (CpG ODN) and synthetic form of double
2stranded RNA (dsRNA), pIC. These are ligands for TLR3 and TLR9, which are members of
diverse innate immune receptors. The delivery system we are utilizing is liposomes. We
analyzed immunostimulatory activities of different liposome-ODN complexes and came up
with several promising formulas.
1.1. The immune system
Colonizing microbes that are detrimental to host are called pathogens. Mammalian
host provide several niches to pathogens such as skin, intestine, upper and lower respiratory
tract, urogenital tract and internal organs. These niches provide optimum living conditions,
such  as  rich  nutrients  and  optimum  temperature  for  pathogens  to  colonize.  However  hosts
need to fight off the invaders. Otherwise damage given by pathogens would be fatal. The
system that prevents microbial colonization is called the immune system.
All living organisms are continuously exposed to foreign entities throughout their life
such as microorganism, poisonous substances, self metabolites and food. If they can
successfully  pass  the  first  line  of  defense  (skin,  mucosa)  they  are  encountered  with  second
line of defense which is the innate (natural) arm of immune system. The foreign, infiltrated
entities need to be discriminated from safe-self entities and they should be eliminated from
the body before they invade the body and damage the host. After their foreignness is
identified by innate immune system, the elimination is mainly performed by adaptive
(acquired) immunity, which is considered as third line of defense.
It was previously known that while response of adaptive immunity is highly specific
to antigens, innate immunity gave relatively less specific immune response. However it was
revealed that innate immune system has greater specificity than previously thought. It was
discovered that innate immune cells can differentiate self from non-self. While innate
immunity remains unresponsive to self entities, it initiates pro-inflammatory response by
involving in antigen presentation and adaptive immunity priming process.
1.1.1. The innate immunity
  The existence of innate immunity was recognized by Russian immunologist Elie
Metchnikoff, who is the discoverer of macrophages. He realized that many microorganisms
are engulfed and digested by phagocytic cells.
3Innate immune system is composed of several modules; mucosal epithelia,
phagocytes, acute phase proteins, complement system, inflammasomes, natural killer (NK)
cells, type-I IFNs and IFN-induced proteins, eosinophils, basophils and mast cells are
members of modules (Medzhitov 2007).
Mucosal epithelial and skin is the main interface between host and pathogen world.
Mucosal epithelial cells and keratinocytes produce antimicrobial proteins that limit
pathogens’ viability and proliferation. Epithelial cells at mucosal surfaces produce mucins,
which prevent pathogens to attach and enter (Medzhitov 2007).
Phagocytosis is crucial for clearance of both intracellular and extracellular pathogens.
It is carried out by macrophages and neutrophils and facilitated by antibodies and opsonins,
which are host products of acute phase response and complements system. Acute phase
proteins are secreted by hepatocytes upon exposure to pro-inflammatory cytokines, IL1β, IL6
and TNFα. The main function of these proteins are opsonizing pathogens for phagocytosis
and activating complement system (Murphy et al. 2008).
Inflammasomes are protein complexes that activate proinflammatory caspases such as
caspase-1,-5,-4,12 (in human). Activated caspases processes IL1 family cytokines, IL1β,
IL18 and IL33. These cytokines have diverse functions in host defense such as initiating
inflammation and acute phase response (Meylan et al. 2004).
NK cells are considered as specialized cells in defense against intracellular pathogens.
They force infected cells to get into apoptosis and produce large amount of IFNγ (Bancroft et
al. 1987; Scharton et al. 1993). They express activating and inhibitory receptors. The ligands
of these receptors are expressed by infected cells. If the activating ligand overrides, NK cell
kills the infected cell, otherwise, the target cell can survive (Lanier 2005).
Type I IFNs (IFNα/β) are produced in response to viral activation. They have critical
roles in defense against viruses. Their production induces more than 100 genes, which have
diverse role in antiviral response. Type I IFNs will be discussed in previous sections in more
detail.
Eosinophils and basophils have role in host defense against multicellular parasites
such as helminthes. They are recruited to the site of infection from blood circulation. They
contain granules with enzymes and toxic proteins. Mast cells reside in mucosal tissues and
4connective tissues. They are believed to have role in protecting the internal surfaces of the
body  from  pathogens  and  parasitic  worms.  Mast  cells  release  granules  upon  activation.
Eosinophils, basophils and mast cells are involved in allergic reactions (Murphy et al. 2008).
The main difference between innate and adaptive immune system is the way they are
recognizing pathogens. Adaptive immune system mediates recognition by antigen receptors.
Somatic recombination of the gene segments expressing antigen receptors enables the
generation of a diverse repertoire of receptors (Schatz et  al. 1992). Innate immune
recognition is mediated by germline encoded pattern recognition receptors.
1.1.1.1. Pattern recognition receptors
Pattern recognition receptors (PRR) recognize molecular structures that are unique to
microorganisms. These structures are called pathogen associated molecular patterns
(PAMPs) although they are also found on non-pathogenic microorganisms. These molecules
are invariant among microorganisms. They are products of pathways that are unique to
microorganisms. This feature enables self-non-self discrimination. Additionally these
structures have vital roles for microorganism. Microorganisms cannot evade innate and
adaptive immune system by changing structure of PAMPs through evolutionary process
(Medzhitov 2007).
Examples of bacterial cell wall PAMPs are lipopolysaccharide (LPS), which is found
only on gram negative bacteria, peptidoglycan, lipoteichoic acids and cell-wall lipoproteins.
β-glucan is PAMP of fungal cell wall. Unmethylated DNA containing cytosine-phosphate-
guanine (CpG) motif in bacterial commonly found on bacterial genome, viral double
stranded RNA (dsRNA), single stranded (ssDNA) are another examples of PAMPs.
Nucleotide binding oligomerization domain (NOD)-like receptors (NLRs) (NALP1,
NALP3, NAIP5, IPAF, ASC, NOD1 and NOD2) and retinoic acid-inducible gene I (RIG-I)
like receptors (RLRs) (DAI, RIG1, MDA5, LGP2) are cytosolic receptors. They are involved
in recognition of bacterial and viral PAMPs. While NLRs recognize viral and bacterial
components, defined RLRs only recognize viral DNA and RNA. C-type lectin receptors
(CLRs) (FcγR, collectins, mannose receptor, DC-SIGN, Dectin-1 Dectin-2, CARD9) are
membrane-bound receptors, which recognize viral, bacterial and fungal components. Most
5studied PRRs are Toll-like receptors (TLRs). 11 different TLR, TLR1-TLR11 was defined to
date. Every TLR recognize different microbial components. (Table 1)
Table 1: Pattern recognition receptors and their ligands. Adopted from (Ishii et al. 2008).
Microbial Signature TLRs RLRs NLRs CLRs
Viruses
Structural proteins
(capsid, envelope
proteins)
TLR2, TLR4
DNA TLR9 FcγR
RNA
TLR3 (dsRNA),
TLR7, TLR8 (ssRNA)
RIG-1,
MDA5
, LGP2
NALP3 FcγR
Bacteria
Cell wall components,
LPS, PGN, lipoteichoic
acid, lipoproteins
TLR2/1, TLR2/6,
TLR4
NOD1, NOD2,
NALP1, NALP3
Collectins (MBL)
Flagellin TLR5 IPAF, NAIP5
Perotoxins NALP3
DNA TLR9 ASC
RNA NALP3
Protozoan
parasites
GPIs TLR2, TLR4
Malaria hemozoin TLR9
Proteins (T. cruzi Tc52,
profilin)
TLR2, TLR11
DNA TLR9
Helminths
Lipids TLR2
RNA TLR3
Fungi
Cell wall components
(GlcNAc, mannan, β-
glucan)
TLR2, TLR4,
TLR6
Mannose
receptor, DC-
SIGN, Dectin-1,
Dectin-2,
CARD9
DNA TLR9
The production of antimicrobial molecules by mucosal epithelia and keratinocytes, is
induced by engagement of TLRs and NOD receptors. During acute phase response, secreted
PRRs, collectins, ficolins and pentraxins are secreted from hepatocyte. Cell autonomous viral
recognition and subsequent NK cell activation ligand expression is mediated by direct TLR3
activation or by recognition of pathogenic entities by cytoplasmic PRRs, RIG-1 or MDA5 or
by cell-autonomous detection of excessive cellular stress. NK cell activation is also
controlled by plasmacytoid dendritic cells, which were activated through TLRs and
6expressing IL15 upon viral infection. Type I IFN production is controlled either by
intracellular  PRRs  or  by  endosomal  TLRs,  TLR3,  TLR7  and  TLR9.  Mast  cells  can  be
directly activated by TLR engagement. (Medzhitov 2007) It is obvious that PRRs have direct
influence on control of innate immune response.
1.1.1.1.1. Toll like receptors
Toll was initially discovered in Drosophila melanogaster as an essential receptor for
embryonic patterning. Subsequently it was understood that Toll is critical component of host
defense against fungal and bacterial infections. (Leulier et al. 2008) Thereafter its human
homolog has been defined. (Medzhitov et al. 1997) TLRs are a group of evolutionarily
conserved proteins belonging to the IL-1R superfamily, characterized by an extracellular
LRR and an intracellular Toll/IL-1 receptor like (TIR) domain. TIR domain of Toll proteins
is a conserved protein-protein interaction module, which is also found in a number of
transmembrane and cytoplasmic proteins in animals and plants have a role in host defense.
(Medzhitov 2001)
1.1.1.1.2. TLRs in innate and adaptive immunity
TLRs in the innate immune system serve an essential role not only in recognition of
pathogen, but also in directing the course and type of innate immune response generated
following exposure to foreign antigen. (Takeda et al. 2003) TLRs have been demonstrated to
have a wide array of functions including initiation of proinflammatory responses and
antiviral responses, up-regulation of costimulatory molecules on antigen presenting cells
(APC), release of chemokines to induce migration of responder cells to the site of infection,
and induction cross-priming of T cells by DCs (Takeda et al. 2005). TLRs have emerged as
essential not only in innate immune responses but also in shaping adaptive immune responses
to pathogen. The signals for activation of adaptive immunity are mostly provided by DCs.
TLR-mediated  recognition  of  pathogens  by  DCs  induces  the  expression  of  costimulatory
molecules such as CD80/CD86 (which provides a costimulatory signal necessary for T cell
activation and survival) and production of inflammatory cytokines such as IL-12 (Iwasaki et
al. 2004) DCs subsets can induce either Th1 and Th2 responses. Activation of TLR9 in DCs
induces production of IL-12, thereby changing the naïve CD4+ T cell differentiation toward
7Th1 type (Iwasaki et al. 2004). LPS stimulates TLR4 signaling pathway and DCs to support
Th1 and Th2 cell differentiation (Kaisho et al. 2002).
1.1.1.1.3. TLR family members
Mammalian TLRs comprise of a large family consisting of at least 11 members.
TLRs play important roles in recognizing specific microbial components derived from
pathogens including bacteria, fungi, protozoa and viruses. It is expressed in a variety of
somatic cell types (Zarember et al. 2002), most predominantly in the cells of the immune
system, including, lymphocytes, macrophages and DCs (Iwasaki et al. 2004; Kabelitz 2007).
TLRs can be subcategorized according to their localization in the cells. TLR1, 2, 4, 5, 6 and
10 which are seemed to specialized in the recognition of mainly bacterial products; are
located on the plasma membrane, whereas TLR3, 7, 8 and 9 that are specialized in viral and
intracellular bacteria detection and nucleic acids, are located in the intracellular endosomal
and/or ER compartments (Iwasaki et al. 2004; Latz et al. 2004).
1.1.1.1.3.1. TLR1, TLR2 and TLR6
 TLR2 responds to various microbial products such as lipoproteins, bacterial PGN
and LTA, lipoarabinomannan of mycobacteria, glycosylphosphatidylinositol anchors of
Trypanosoma cruzi, a phenol-soluble modulin of Staphylococcus epidermis and zymosan of
fungi (Takeda et al. 2005). One of the aspects proposed for the wide spectrum recognition of
microbial components TLR2 recognizes, is that TLR2 forms heterophilic dimers with other
TLRs such as TLR1 and TLR6, both of which are structurally related to TLR2. The studies
done with the TLR6 or TLR1 deficient mice showed no inflammatory response to
mycoplasma-derived triacyl and diacyl lipopeptides respectively. TLR2 defective mice did
not show any response to both triacyl and diacyl lipopeptides. (Takeda et  al. 2002) This
proves that TLR1 and TLR6 functionally associate with TLR2 and have role in
discriminating diacyl or triacyl lipopeptides. In addition to that TLR2 has been shown to
functionally collaborate with distinct types of receptors such as dectin-1, a CLR family
receptor for the fungal cell wall component β-glucan. It was reported that TLR2 triggers
TNF-α and MIP-2 secretion from macrophages through the MyD88 signaling pathway with
yeast C. albicans. (Gil et al. 2006) It has been revealed that PGN could also be delivered to
8the cytosol for NOD1 recognition from extracellular sites or from phagocytosed bacteria
(Chamaillard et al. 2003).  Therefore  we can  suggest  that  for  the  recognition  of  PGN,  TLR
and NLR could act together.
1.1.1.1.3.2. TLR3
The discovery of double-stranded (ds) RNA as the ligand for endosomal located
TLR3 helped recognize that TLRs may have a key role in the host defense against viruses by
enhancing NF-κB  and interferon (IFN)-regulatory factor 3 (IRF3) pathways (Alexopoulou et
al. 2001; Matsumoto et al. 2003). As exceptions, inflammatory cell of lamina propria express
TLR3 on cell surface during active Crohn’s disease (Cario et al. 2000). In addition to dsRNA
viruses, most viruses during their replication synthesize and induces the production of type I
interferons (IFNα/β), which exert anti-viral and immunostimulatory activities. NK cells are
the major players in the antiviral immune response and express TLR3 and are activated
directly in response to synthetic dsRNA, polyinosinic acid:cytidylic acid (pIC) (Schmidt et
al. 2004). While viral nucleic acid recognition by TLR7/8 and TLR9 preferentially expressed
on plasmacytoid dendritic cells induces high amount of type I IFNs, TLR3 expressed
myeloid dendritic cells and macrophages induces high amount of type I IFN secretion and
IL12 in response to pIC (Siegal et al. 1999; Kadowaki et al. 2001; Colonna et al. 2004).
TLR3 in DCs recognize viral infection in phagocytosed dying cells (Schulz et al. 2005).
Moreover TLR3 interacts with CD14, which binds dsRNA and facilitates the uptake of
dsRNA into endosome (Lee et al. 2006). Upon TLR3 activation by dsRNA, PI3K is recruited
to phosphorylated tyrosine residues of TLR3 and supports the activation of IRF3 which
induces transcription of Type I IFNs. Besides, TRIF associating with TBK1 through TRAF3
and NAP1 phosphorylates and activates IRF3, which in turn activates activation of IFNα/β.
Moreover tyrosine kinase c-Src also associates with TLR3 to activate IRF3. However the
precise role of c-Src could not be fully understood yet.  (Honda et al. 2006) Please see Figure
1B for TLR3 mediated Type I IFN induction pathways.
9Figure 1A-C: TLR mediated Type I IFN Induction Pathways. Adapted from (Honda et al. 2006).
1.1.1.1.3.3. TLR4
Human TLR4 was the first identified mammalian Toll (Poltorak et al. 1998). This
extracellular TLR is expressed in variety of cell types, most predominantly in macrophages
and DCs (Medzhitov et al. 1997). TLR4 functions as the signal-transduction for signal-
transducing receptor for lipopolysaccharide (LPS) which is a major component of the outer
membrane of Gram-negative bacteria (Hoshino et al. 1999). Recognition of LPS by TLR4 is
complex and requires several accessory molecules. LPS is first bound to a serum protein,
LPS-binding protein (LBP), which functions by transferring LPS monomers to CD14
(Wright et al. 1989). CD14 is a high-affinity LPS receptor that can either be secreted into
serum,  or  expressed  as  a  glycophosphoinositol  (GPI)-linked  protein  on  the  surface  of
macrophages. Another component of the LPS receptor complex is MD-2 (Shimazu et al.
1999). Although its precise function is not known, MD-2 is required for LPS recognition
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(Schromm et al. 2001).  In addition to LPS, TLR4 is involved in the recognition and is
considered to be an accessory protein other ligands, including LTA, and a heat-sensitive cell-
associated factor derived from Mycobacterium tuberculosis (Li et al. 2001). Interestingly,
TLR4 and CD14 were also shown to trigger a response to the fusion (F) protein of respiratory
syncytial virus (RSV).  Since it is not clear yet whether the F protein of RSV represents an
example  of  a  viral  PAMP,  an  alternative  possibility  is  that  the  RSV  evolved  the  ability  to
stimulate TLR4 for its own benefit (Kurt-Jones et al. 2000). TLR4 is the only TLR that can
induces Type I IFN secretion. It is regulated through Trif-dependent pathway. TBK1
associating with TRIF through NAP1 and TRAF3 phosphorylates and activates IRF3.
Activated IRF3 localize to nucleus and activates expression of IFNα/β genes. TLR4 utilizes
the same pathway for Type I IFN induction with TLR3 mediated type I IFN induction
(Figure 1a,b).
1.1.1.1.3.4. TLR5
TLR5 recognizes flagellin, the protein subunits that make up bacterial flagella from
gram positive and gram negative bacteria (Hayashi et al. 2001). Flagella is recognized by the
innate immune system of mammals(Wyant et al. 1999) and plants (Gomez-Gomez et al.
2000). It induces TNFα and IL6 secretion through MyD88 dependent pathway (Hayashi et al.
2001).
1.1.1.1.3.5. TLR7/8
Both of these TLRs are structurally highly conserved proteins, and recognize the
same ligand in some cases.  Although both TLRs are expressed in mice, mouse TLR8
appears to be nonfunctional (Akira et al. 2006). It has been revealed that murine and human
TLR7 (but not murine TLR8) recognizes synthetic compounds, imidazoquinolines (R848),
which are clinically used for treatment of genital warts associated with viral infection
(Hemmi et  al. 2002). Murine TLR7 and human TLR8 recognize guanosine or uridine-rich
single-stranded  RNA  (ssRNA)  from  viruses  such  as  HIV,  vesicular  stomatitis  virus  and
influenza virus. Unless host-derived ssRNA is presented to endosomes, they are not detected
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by TLR7 or TLR8. This might be due to the fact that TLR7 and TLR8 are not engaging with
ssRNA (Lund et al. 2004).
1.1.1.1.3.6. TLR9
The most extensively studied TLR is TLR9. It recognizes unmethylated CpG
dinucleotides which are common in bacterial and viral genome but suppressed and
methylated in vertebrate genomes. The reason of the epigenetic difference between bacterial
or viral genome and vertebrate genome is that bacteria lack cytosine methylation mechanism.
Thus genome of pathogens is good marker for host to distinguish self and non-self. TLR9 is
primarily  expressed  on  B  cells,  NK  cells  and  DCs  After  encountering  of  TLR9  with  its
ligand, TLR9 expressing immune cells proliferate, mature and secrete various cytokines (IL-
12, IFN-g, IL-6), chemokines or immunoglobulins (Ig) (Krieg 2000). A single nucleotide
substitution or methylation of a cytosine residue within the CpG motif completely abrogates
the immunostimulatory property of bacterial DNA (Krieg et al. 1995).
There are at least two types of synthetic CpG DNA, termed A or D-type CpG DNA
and B or K-type CpG DNA (Klinman 2004). B/K-type CpG DNA is made up of
phosphorothioate backbone and possesses more than one CpG motifs on a single backbone,
and  is  a  potent  inducer  of  inflammatory  cytokines  such  as  IL-12,  IL-6  and  TNF-α,  B  cell
proliferation and IgM secretion. A/D-type CpG DNA is structurally different from B/K CpG
DNA, which are phosphodiester/phosphorothioate mixed backbone, and G-runs at 3’–5’
ends, and a single CpG motifs has a greater ability to induce IFN-α production from pDCs,
but inability to induce B-cells (Verthelyi et  al. 2001; Gursel et  al. 2002). TLR9 has been
shown to be essential for the recognition of both types of CpG DNA (Hemmi et al. 2003). In
addition to bacterial CpG DNA, TLR9 has been shown to recognize viral-derived CpG DNA
in pDC such as herpes simplex virus (Krug et al. 2004).
Although both type of ODN are recognized by TLR9 there is dichotomy between K
and  D  type  CpG  ODN  on  human  cells.  It  was  revealed  that  the  the  reason  of  differential
immune activation might be membrane bound scavenger receptor known as CXCL16
expressed on pDC. Higher ordered structure (G-tetrad) of D-ODN have role in recognition of
D-ODN by CXCL16. D-ODN most probably binds to CXCL16 by the help of G-tetrads
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(Gursel et  al. 2006). Recognition of D-ODN by CXCL16 might sequester it into early
endosomes for a long time while K-ODN immediately localize to lysosomal vesicles. After
recognition of K-ODN in late endosome, MyD88 and IRF5 colocalize with TLR9 and induce
TNFα secretion (Asselin-Paturel et al. 2005).  Following D-ODN recognition by TLR9 in
early endosome of pDCs, MyD88 and interferon regulatory factor (IRF)-7 colocalize with
TLR9 and subsequent downstream signaling induces IFNα production. However in
conventional  dendritic  cells,  D-ODN is  rapidly  transferred  to  lysosomal  vesicles  (Figure  2)
(Honda et al. 2005). This spatiotemporal regulation of MyD88-IRF7 pathway in DCs might
be the reason of high interferon secretion by pDCs. Prolonged signaling allows continuous
activation of the positive feedback system and phosphorylation of de novo synthesized IRF7
to induce robust type I IFN production (Asselin-Paturel et  al. 2005; Honda et al. 2006).
Please see Figure 1c.
Figure 2: Signaling of D and K-ODN classes in different subcellular compartments of
plasmacytoid dendritic cells. Adapted from (Gilliet et al. 2008)
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Bacterial and viral CpG DNA and TLR9 are presumably involved in pathogenesis of
autoimmune disorders. For instance, immunoglobulin-G2a (IgG2a) might bind to
autoantigens such as intact nucloesomes, DNA or histones.  The immune complexes are
recognized by B cell receptor (BCR), its internalization is facilitated.  Nucleososmes
including hypomethylated CpG motifs, is then able to engage TLR9, thereby inducing
autoimmune diseases such as systemic lupus erythematosus (Viglianti et al. 2003). More than
a dozen of human clinical trails have been initiated utilizing TLR9 agonists. It seems likely
that  the  targeted  activation  of  TLR9 using  CpG ODN will  enhance  the  treatment  of  cancer
and infectious diseases, as well as showing new hopes for reducing the harmful inflammatory
responses such as, asthma and other allergic diseases (Krieg 2006).
1.1.1.1.4. TLR signaling pathways
Activation  of  TLRs by  PAMPs leads  to  induction  of  various  genes  that  involved  in
host defense, including inflammatory cytokines, chemokines, MHC and co-stimulatory
molecules. Mammalian TLRs also induce multiple effector molecules such as inducible nitric
oxide synthase (iNOS) and antimicrobial peptides, which can directly eliminate microbial
pathogens (Thoma-Uszynski et al. 2001). Although both TLRs and IL-1Rs rely on TIR
domains to activate NF-κB and MAP kinases and can induce some of the same target genes,
a growing body of evidence points to several differences in signaling pathways activated by
individual TLRs. Besides, activation of specific TLRs lead to slightly different patterns of
gene expression profiles. For example, activation of TLR3 and TLR4 signaling pathways
results in induction of type I IFNs, (Doyle et al. 2002) but activation of TLR2- and TLR5-
mediated pathways does not (Hoshino et al. 2002).  In addition to TLR3 and TLR4, TLR7,
TLR8 and TLR9 signaling pathways also lead to induction of type I IFNs but in a different
manner (Ito et al. 2002). It has been revealed that there are MyD88-dependent and MyD88-
independent/TRIF dependent signaling.
1.1.1.1.4.1. MyD88 Dependent Pathway
The role of Toll-mediated recognition in the control of MyD88 protein was studied
using MyD88-deficient mice. A MyD88-dependent pathway is analogous to signaling
pathways through the IL-1 receptors. MyD88, including a C-terminal TIR domain and an N-
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terminal death domain, joins with the TIR domain of TLRs. After stimulation, MyD88
recruits IL-1 receptor-associated kinase-4 (IRAK-4) to TLRs by the interaction of the death
domains of both molecules, and facilitates IRAK-4-mediated phosphorylation of IRAK-1.
Activated IRAK-1 then associates with TRAF6, leading to the activation of two distinct
signaling pathways. One pathway leads to activation of AP-1 transcription factors through
activation  of  MAP  kinases.  Another  pathway  activates  the  TAK1/TAB  complex,  which
enhances  activity  of  the  Inhibitor  kappa  B  kinase  (IkK) complex. Once activated, the IkK
complex induces phosphorylation and subsequent degradation of IkB, which leads to nuclear
translocation of transcription factor NF-kB (Takeda et al. 2004). MyD88-deficient mice do
not show production of inflammatory cytokines such as TNF-α and IL-12p40 in response to
all TLR ligands (Takeuchi et al. 2000; Klinman 2004). This once again proves that MyD88 is
essential for inflammatory cytokine production through all TLRs. MyD88-deficient
macrophages, show impaired inflammatory cytokine production in response to TLR4 and
TLR2 ligands in contrast to TLR3, TLR5, TLR7 and TLR9 ligands (Yamamoto et al. 2002).
For brief summary, please see Figure 3.
1.1.1.1.4.2. MyD88-independent-TRIF dependent pathway
TLR4 ligand-induced production of inflammatory cytokines is not observed in
MyD88-knock-out macrophages; on the other hand, delayed NF-κB expression is observed.
This shows that although TLR4 signaling depends on MyD88-dependent pathways, a
MyD88-independent component exists in TLR4 signaling. TLR4-induced activation of IRF-3
leads to production of IFN-β. IFN-β in turn activates Stat1 and induces several IFN-inducible
genes, like TLR3 (Yoneyama et al. 1998; Alexopoulou et  al. 2001). TRIF-deficient mice
generated by gene targeting showed impaired expression of IFN-β- and IFN-inducible genes
in response to TLR3 and TLR4 ligands (Yamamoto et al. 2002). Studies with the other
TRIF-related adaptor molecules (TRAM)/TICAM-2 showed that TRAM is involved in
TLR4-mediated, but not TLR3-mediated, activation of IRF-3 and induction of IFN-β and
IFN-inducible genes (Yamamoto et al. 2003), so TRAM is essential for the TLR4-mediated
MyD88-independent/TRIF-dependent pathway. Key molecules that mediate IRF-3 activation
have been revealed to be non-canonical IkKs, Tank binding kinase-1 (TBK1) and IkKi/IkKe
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(Fitzgerald et al. 2003). It has been recently reported that, complete MyD88 and TRIF
expression is required for the effective cooperation, resulting in the induction of IL-12, IL-6,
and IL-23 but not of TNF-α and IP-10 upon MyD88- and TRIF-dependent TLR stimulation.
Downstream of MyD88, TRIF and IRF5 were identified as an essential transcription factor
for the synergism of IL-6, IL-12, and IL-23 gene expression (Ouyang et al. 2007). Since
TRAF6 is critically involved in TLR mediated NF-κB activation, and TRAF6 associates the
N terminal portion of TRIF (Gohda et al. 2004) and the association of C-terminal portion of
TRIF with Receptor-interacting protein-1 (RIP1) (Meylan et  al. 2004) leads to NF-κB
activation. For brief summary please see Figure 3.
Figure 3: TLR Signaling Pathways. Adapted from (Akira et al. 2004)
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1.2. Liposomes as delivery system
1.2.1. Liposomes: a historic brief
Since its invention at 1964 by Dr. Alec D. Bangham, hundreds of studies have been
performed to make liposomes appropriate for biomedical applications such as drug delivery
systems, transfection reagents, red blood cell substitutes, vaccine delivery systems and
vaccine adjuvants.  Use of liposomes as carriers of peptide, protein, and DNA vaccines
requires simple, easy-to-scale-up technology capable of high-yield vaccine entrapment. Last
20 years eventually have resulted in the approval of several liposomal drugs and biomedical
products and technologies involving liposomes (Torchilin 2005).
Liposomes are spherical structures formed by several concentric lipid bilayers with an
aqueous phase inside and between the lipid bilayers. They form self closed structures in
water due to hydrophilic and hydrophobic interactions between phospholipids and water.
There are different types of vesicles; Large multilamellar vesicles (LMV) range in size from
500nm to 5μm and consist of several bilayers. Small unilamellar vesicles (SUV) consist of
single bilayer and they are around 100nm in size. Large unilamellar vesicles range in size
from 200nm to 800nm and formed by single bilayer. Long circulating liposomes are
modified in a way that they could not be cleared rapidly by reticuloendothelial system (RES).
The modification is usually a surface grafting with certain polymers such as polyethylene
glycol (PEG). Immunoliposomes carry antibodies attached to their surface and able to
accumulate in the area within the body where the attached antibody recognizes its antigen.
Long circulating immunoliposomes are kind of liposomes with combined properties of long
circulating liposomes and immunoliposomes. They are not cleared from blood circulation
rapidly and can accumulate at their target efficiently (Torchilin 2005)
1.2.2. Advantages and disadvantages of liposomes
Liposomes are biocompatible materials. They can entrap both water-soluble and
insoluble pharmaceutical agents in their aqueous compartment and into membranes
respectively. Liposomes protect liposome-incorporated pharmaceuticals from uptake by cells
of RES or other inactivating effects such as cleavage of nucleic acids or proteins by
nucleases and proteases in blood or rapid clearance due to serum protein absorption.
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Liposomes can deliver pharmaceuticals into cells or even inside individual cellular
compartments (Torchilin 2005). Liposomes do not accumulate appreciably in tissues such as
hearth, kidneys and gastrointestinal tract. Therefore side effects of encapsulated drugs which
are toxic to these organs could be lowered (Gregoriadis 1984). Besides size, charge and
surface properties of liposomes can be easily changed simply by adding new ingredients to
the lipid mixture before liposome preparation and or by variation of preparation methods.
(Torchilin 2005)
Liposome technology has some disadvantages beside remarkable advantages. Full
physicochemical characterization of liposomes is needed in early stages, which can be used
to obtain regulatory approval for the liposome product. Nevertheless poor characterization of
diverse array of liposomes complicates the optimization steps and delays their clinical usage.
For a pharmaceutical product a minimum shelf life of two years, preferably without
refrigerator cooling is a requirement. Liposomes are not that much stable. Sterile preparation
of liposomes could be done by autoclaving. This is not a realistic option if labile drugs are
being utilized. Moreover organic components such as ethanol or chloroform that are used
during manufacturing of liposomes should be removed completely. Residual organic solvents
might be carcinogenic during chronic usages (Crommelin et al. 2003).
1.2.3. Delivery of TLR ligands in liposome
Rapid  clearance  of  TLR  ligand  nucleic  acids  such  as  CpG  ODN  and  pIC,  hampers
their biomedical applications. To prevent premature clearance of CpG ODN by nucleases
found in the blood, more stable backbone is used to synthesize CpG-ODN (a
phosphorothioate modified form). However when they were used in vivo, they were still
eliminated rapidly from the circulation due to the absorption onto serum proteins and
degradation by serum nucleases (Barry et al. 1999). Prolonging the bioavaliabilty and
duration of CpG ODN by liposomal encapsulation can improve their therapeutic efficiency.
Hopefully it was shown that, sterically stabilized cationic liposomes (SSCL) contain
positively charged phoshoplipid and polyethylene glycol can significantly enhance DNA
uptake by cells of the immune system. The immunostimulatory activity of SSCL-
encapsulated ODN significantly exceeded that of free ODN in vitro and in vivo. In particular,
coencapsulation of CpG ODN with a model Ag ovalbumin (OVA) increased Ag-specific
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IFN-g production (10-fold) and IFN-g-dependent IgG2a anti-OVA antibody production (40-
fold), consistent with the preferential induction of a TH1-biased immune response (Gursel et
al. 2001; Klinman et al. 2004).  Many article in the literature reports enhanced
immunostimulatory activity of CpG ODN encapsulated or coencapsulated with an antigen
into various types of liposomes (Li et al. 2003; Suzuki et al. 2004; Jaafari et al. 2007; Badiee
et al. 2008; Wilson et al. 2009).  Moreover  there  are  some studies  showing that  CpG ODN
encapsulating liposomes can be utilized in anticancer therapies (Ishii et al. 2003; de Jong et
al. 2007; Hamzah et al. 2009).
In addition to that co-administrating CpG ODN in polylactide-co-glycolide (PLG;
another cationic microparticle that improves the uptake and processing of immune adjuvants)
with the licensed anthrax vaccine, “AVA”, resulting in a more rapid and stronger anti-
protective antigen antibody response; IgG, than immunization with AVA alone in vivo (Xie
et al. 2005). Not only CpG ODN but also pIC has been co-administrated with cationic
liposomes and thereby elevated the type I IFN, IFN-a production and have a unique effective
on CD8+ T  cell  responses in vivo (Zaks et  al. 2006). Besides, CpG delivery could be
achieved by natural carriers, such as a b-(1à3)-D-glucan schizophyllan (SPG)
polysaccharide of a fungus called Schizophyllan commune. When SPG is modified with other
peptides and cholesterol and complexed with CpG ODN induces dramatic enhancement in
secretion of cytokines such as IL-6 and IL-12 by macrophages (Mizu et al. 2004).
1.2.4. Nucleic acid encapsulation methods in liposomes
There are several ways of encapsulating nucleic acids in liposomes. The first
approach is called preformed vesicle approach (PFV). It employs incubation of large
unilamellar vesicle (LUV) containing a cationic lipid and PEG with oligo or polynucleic
acids  in  the  presence  of  ethanol.  The  use  of  membrane  destabilizing  agent,  ethanol,  in
conjunction with PEG-lipid enables controlling the interaction between negatively-charged
polyelectrolytes and cationic liposomes and result in the encapsulation of nucleic acids in
liposomes. After incubation time for encapsulation is over, ethanol is removed by dialyzing
(Gregoriadis 2007).
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Second way of nucleotide encapsulation in liposomes is detergent dialysis procedure.
In  contrast  to  PFV approach,  the  detergent  dialysis  procedure  starts  with  a  micellar  system
and the encapsulation is obtained after removal of detergent by dialysis. Nucleic acids are
encapsulated into unilamellar vesicles called stabilized plasmid-lipid particles (SPLP)
(Gregoriadis 2007).
An alternative method of nucleic acid encapsulation is called dehydration-rehydration
protocol. The first step of the protocol is generating LUV by suspending mixture of lipids in
water. If desired, LUV can be turned into SUV by sonicating the liposomes. After nucleic
acid or protein solution is added onto liposomes, the mixture is freeze dried. At this step,
aqueous compartment of liposomes is emptied and bilayers collapse on themselves
(dehydration). Then water is added onto liposomes. Water dissolves the materials at the
periphery  of  liposomes  and  starts  to  diffuse  into  liposomes.  This  is  the  time  when  the
encapsulation occurs (Gregoriadis et al. 1999).
We have preferred to use dehydration-rehydration protocol rather than PFV or
detergent dialysis procedure. Because the materials we have used (CpG ODN, pIC, OVA) are
labile molecules. Ethanol used in PFV approach or detergent used in detergent dialysis
procedure would alter their structure which would affect their activities. Besides,
encapsulation ratios obtained by dehydration-rehydration protocol is higher than other
methods (Gregoriadis et  al. 1999) (Please see Table 7 in the Results Section).
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2. AIM OF THE STUDY
Without doubt TLR ligands will be in therapeutics in near future. They are candidate
of immunotherapeutic agents for anticancer, antiviral and antibacterial therapy. They might
be used to treat allergy or utilized as vaccine adjuvant. Moreover, they can be harnessed as
stand alone immunoprotective agents to provide instant protection against pathogenic insults
where proper vaccines are not available.
Nucleic acids with bacterial and viral origins (and their synthetic forms) are ligands
of endosomal TLRs. They are potential immunotherapeutic agents however their clinical
applications are hampered due to premature in vivo digestion by endonucleases and rapid
clearance via serum protein absorption leading to limited stability and activity. This problem
can be overcome by encapsulating TLR ligands in liposomes, which increase in vivo stability
as well as augment targeting and internalization to relevant innate immune cells.
The major plan is to assess the immunostimulatory activities of five different
liposome encapsulating pIC and two types of CpG ODN, K-ODN and D-ODN both in vitro,
ex vivo and in vivo animal model. Since liposomes possess different physicochemical
properties, we anticipate that this will be translated into a differential immunostimulatory
activity mediated by the liposomes encapsulating same cargo. Therefore, we needed to try
each of them separately. In order to improve the in vivo bioavailability coupled with stability
and internalization/targeting of the labile nucleic acid TLR ligands pIC and CpG ODN were
selected as the major cargo components throughout this study. Moreover, pIC and CpG ODN
are known to trigger Th1 type cytokine secretion such as IFNγ, IL6, IFNα/β, and IL12 which
are critical mediators of defense against viruses and bacteria. The necessity for designing
such  a  formulation  will  also  allow  us  to  co-encapsulate  antigen  of  interest  in  the  same
liposome vesicles, thus ensuring their simultaneous presentation to relevant immune cells in
a depot fashion.
Following the initial screening and potency determination experiments, the final stage
of this thesis will be dedicated to utilize the most promising candidate formulation in a model
vaccination experiment in mice.
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3. MATERIALS AND METHODS
3.1. MATERIALS
3.1.1. Reagents
All  cell  culture  media  components  were  from  Hyclone  (USA).  Cytokine  ELISA
reagents; i) monoclonal unlabeled and biotinylated antibodies against IL6 and IFNγ were
purchased from Thermo Scientific (USA) and Endogen Pierce (USA) respectively. ii)
Recombinant cytokines, iii) streptavidine-alkaline phosphatase (SA-AKP) were also bought
from Endogen (USA). iv) p-nitrophenyl phosphate disodium salt (PNPP) - substrate for
alkaline phospahatase, was purchased from Thermo Scientific, (USA). Immunoglobulin
ELISA reagents; goat anti-mouse IgG, IgG, IgG2a, IgG3b monoclonal antibodies conjugated
with alkaline phosphatase (AP) were obtained from Southern Biotech (USA). Ovalbumin
(OVA) was obtained from “Imject OVA” kit of Pierce (USA).
DNase/RNase free water was obtained from Hyclone (USA). TRI Reagent (Trizol)
for  RNA  isolation  was  from  Invitrogen  (USA). DyNAmoTM cDNA Synthesis kit,
DyNAzyme™ II PCR Master Mix for PCR was obtained from Finnzymes (Finland).
10-150 bp DNA ladder was from Fermentas, and 100-1000 bp DNA ladder was from
Jena Bioscience.
L-α-Phosphatidylcholine (PC) was purchased from Sigma Aldrich (USA).
Cholesterol (Chol), 3ß-[N-(N',N'-Dimethylaminoethane)-carbamoyl]Cholesterol
Hydrochloride (DC-Chol), 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N-
[Methoxy(Polyethylene glycol)-2000] (Ammonium Salt) (PEG-PE), 1,2-Dioleoyl-sn-
Glycero-3-Phosphoethanolamine (DOPE) were all from Avanti Polar Lipids (USA).
Heidolph Laborota Collegiate Rotary Evaporator (Germany) and Maxi Dry Lyo, Heto-Holten
(Denmark) freeze dryer were used during liposome preparation.
3.1.2. TLR Ligands
TLR ligands for stimulation assays were as follows and supplied from several
vendors: peptidoglycan (PGN) isolated from B.subtilis; (Fluka, Switzerland),
lipopolysaccharide (LPS) (isolated from E.coli; Sigma, USA), poly inosinic acid: cytidylic
acid (pIC) (Amersham, UK) and CpG and control GpC ODNs (please see Table 2 for details)
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were  synthesized  by  Alpha  DNA (Montreal,  Canada),  and  was  kind  gift  by  Dr.  Dennis  M.
Klinman (NCI/NIH, USA). All ODNs were free of endotoxin and protein. Sequences of CpG
ODNs are summarized at the table below. Bases shown in capital letter have
phosphorothioate and those in lower case have phosphodiester backbone. CpG or flip (GpC)
motifs are underlined.
Table 2. CpG ODNs that are used in stimulation experiments.
ODN Name and Size Sequence
1555 (15mer) GCTAGACGTTAGCGT
K23  (12mer) TCGAGCGTTCTC
D35  (20mer) GGtgcatcgatgcaggggGG
D3CG  (20mer) GGtcgatcgatcgaggggGG
1612  (15mer) GCTAGAGCTTAGGCT
I-127 (20mer) GGtgcatgcatgcatgcaggggGG
Nucleotides shown in capital letter have phosphorothioate backbone and those in lower case have
phosphodiester backbone.
3.1.3. Standard Solutions, Buffers, and Culture Media
See appendix A.
3.2. METHODS
3.2.1. Maintenance of animals
Adult male or female BALB/c or C57/BL6 mice (8-12 weeks old) were used for the
in vivo experiments  as  well  as  generating  primary  spleen  cells  for in vitro stimulations
throughout this thesis. The animals were kept in the animal holding facility of the
Department of Molecular Biology and Genetics at Bilkent University under controlled
ambient conditions (22 ±2°C) regulated with 12-hour light and 12-hour dark cycles. They
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were provided with unlimited access of food and water. All experimental procedures have
been approved by the animal ethical committee of Bilkent University (Bil-AEC).
3.2.2. Liposome Preparation
Cholesterol and various phospholipids (Avanti Polar Lipids, Alabaster, AL) were
combined in different ratios as shown in Table 3. Lipid stocks were prepared in chloroform at
stock solution 10mg/ml and were stored at -40°C until use.
Chloroform was evaporated in a round bottom flask using a rotary evaporator at
37°C.  (Heidolph, Laborota, Germany) The solvent free lipid film was purged with argon or
nitrogen to eliminate residual chloroform and oxygen, thereby preventing lipid peroxidation.
To generate empty multilamellar vesicles 1ml of PBS was added to each 20μmol dried lipid
film.   The  mixture  was  sonicated  for  30  s  each  time for  5  times  at  4°C using  a  Vibra  Cell
Sonicator (Sonics and Materials, Danbury, CT) The small unilamellar vesicles were then
mixed with 1mg/ml ODN, frozen in liquid nitrogen and freeze dried overnight. (Heto-Holten,
Maxi-Dry Lyo, Denmark) ODN encapsulation was achieved during rehydration step.
DNase/RNase free dH2O was added to dehydrated ODN/liposome powder and vortexed for
15 s every 5 min for 30 minutes at room temperature. PBS was added to the mixture yielding
a final liposome concentration of 20μM lipid/mg DNA. Liposome formulations were stored
at 4°C until use.
Table 3: Lipid composition and molar ratios for different liposome types
Liposome Type Liposome Composition (molar ratio)
Neutral PC:Chol (1:1)
Anionic PC:DOPE:PS (1:0.5:0.25)
Cationic DC-Chol:PC:DOPE (4:6:0.06)
Stealth Chol:DOPE:PEG-PE (4:6:0.06)
Cationic-stealth (SSCL) DC-Chol:DOPE:PEG-PE (4:6:0.06)
PC, phosphatidylcholine; Chol, cholesterol; DOPE, dioleylphosphatidylethanolamine; PS,
phosphatidylserine; DC-Chol, dimethylaminoethanecarbamol-cholesterol; PEG-PE,
polyethylene
Representations of five types of liposomes encapsulating ODN is shown in Figure 4.
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        Figure 4: Schematic diagrams of produced liposomes
3.2.3. Determination of ODN encapsulation
50μl of every liposome-ODN formulation was centrifuged for 1hour at 16100xg.
Supernatant was collected into eppendorf tubes. Non-encapsulated ODN concentration in the
supernatant was determined by OD measurements at 260 and 280nm wavelengths with the
spectrophotometer NanoDrop® ND-100 (NanoDrop Technologies, USA). Amount of ODN
encapsulation was determined by subtracting the amount of non-encapsulated ODN from the
original input amount and dividing it to the original input ODN amount that was initially
mixed with empty SUVs before freezing and drying.
3.2.4. Cell Culture
3.2.4.1. Single Cell Suspension Preparation
Mice were euthanized by cervical dislocation. Spleens were removed with sterile
instruments and put into 2 ml 2% FBS supplemented regular RPMI media in 6-well plates. In
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sterile cell culture conditions, single cell suspensions were obtained by smashing spleens
with the back side of a sterile syringe in media with circular movements. Homogenous part
of media was collected by using sterile plastic pasteur pipettes while cell clumps belonging to
fibrous or connective tissue were left. Cells were centrifuged at 1500 rpm for 10 minutes at
room temperature. Medium was sucked cell pellet was gently resuspended in 10 ml fresh
media and centrifuged at the same conditions. These washing steps were repeated twice to
remove remaining tissue debris. At the end of last washing step, cells were resuspended in 10
ml 5% FBS supplemented regular RPMI and counted.
3.2.4.2. Cell Counting and Layering
After  cells  are  resuspended  in  10  fresh  media  as  indicated  above,  10 ml from these
cell suspensions was taken and diluted 10 fold with 90 ml medium to reduce the cell number
in the final 100 ml solution. 10 ml from diluted solution was placed on Neubaer cell counting
chamber. Cells in 4 corners (composed of 16 small squares) with 1mm2 area were counted
under light microscope (Figure 5).
1mm
1mm
 Figure 5: Neubaer cell counting chamber
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The depth between coverslip and cell counting chamber is 0.1 mm. Thus, each 1 mm2
area holds a volume of 0.1 mm3.  So,  the  number  of  cells/ml  can  be  obtained  from  the
equation given below:
Total Cell Number in 4 1mm squares
4
Number of cells per 0.1mm3
x Dilution factor x 104 = number of cells per ml
After total cell number was determined, original cell stock was centrifuged and
resuspended in an appropriate volume of 5% FBS supplemented oligo medium if cells were
to be stimulated with ODNs. If stimulation with ODNs was not to be performed, cells were
resuspended in 5% FBS supplemented regular medium. Working cell concentration was
adjusted to 4x106 cells/ml for ELISA experiments, 1x107cells/ml for RNA extraction and
2x106 cells/ml for FACS analysis unless otherwise stated.
3.2.5. Stimulation Protocols
3.2.5.1. Cell Stimulation
For stimulation in 96-well cell culture plates, 100 ml of 4x106 cells/ml stock (400,000
cells) were transferred to 96-well plates. Total volume was completed to 200 ml with ODN
solution in 100 ml, 5% FBS supplemented oligo medium. Unless otherwise stated, final
concentration  of  CpG  ODNs  was  from  0.3  to  3.0 mM, and pIC was between 1μg/ml to
25μg/ml. Stimulations are performed in triplicate wells for each indicated treatment.(Gursel
et al. 2001) Supernatants are collected after 24-48h for analysis of secretion of various
cytokines. For FACS analysis, 1ml of original cell stock (2x106 cells) was transferred to 15
ml falcon tube. For gene expression studies 500μl of original cell stock (1x107 cells) was
transferred into 15 ml falcon in 5% FBS oligo medium. Total volume was completed to 1 ml
with specific ODNs in 500μl 5% FBS supplemented oligo medium. Final oligo concentration
was 1μM, unless otherwise stated. For gene expression studies, incubation periods were 2-8
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hours while incubation periods were 6-72 hours for FACS analysis depending on the marker
to be examined. Falcon tubes were left in tilted position with loosened caps to allow airflow
and lids of 96-well plates were closed during the incubation period in CO2 incubator.
3.2.6. In vivo experiments
3.2.6.1. Injection of animals with different liposomal ODN or pIC or D35 plus pIC
co-encapsulating different types of liposomes.
BALB/C mice was injected ip with either 25μg or 50μg of free D35 or free pIC or
their free combinations (for 25μg, 12.5 μg of each stimulant was mixed and injected or for
50μg, 25 μg of each stimulant mixed and injected together). Mice were also ip injected with
10μg or 20μg D35 encapsulating 5 different types of liposome formulations. Third set of
mice were injected with 10μg or 20μg pIC encapsulating 5 different types of liposome
formulations. The last set of animal cohort was ip injected with 10μg or 20μg co-
encapsulating D35 plus pIC within 5 different liposome formulations (here, each stimulant
was adjusted to encapsulate 1:1 (wt/wt ratio) of D35 and pIC. 4 hours later mice were
sacrificed and their spleens were extracted and split into two fractions. One half of the spleen
was  used  to  extract  total  RNA  for  PCR  studies.  From  the  other  half,  4x105 cell/well were
incubated for 48 hours in 96 well plates. After incubation, the ex vivo stimulation was
monitored and at this stage there are no further stimulations. The cell supernatants were
collected and layered into IL6 and IFNγ monoclonal antibody coated ELISA plates.
Additionally, 2x106 cells from each treated animals were incubated in 15ml falcon tubes.
After 24 hours of incubation cells were fixed and stained for anti-CD86 expression.
3.2.6.2. Immunization protocol with specific ODNs and OVA
Three to five adult male C57/BL6 mice per group were injected intraperitoneally (ip)
with 15 μg of D35, D35 encapsulated anionic liposomes or control ODN and 7.5 μg of OVA.
Fourteen days later, booster injection was performed ip with the same ODN and OVA
formulations. Animals were tail bled one day before each injection and on the twenty-seventh
day. Blood was incubated (to obtain mouse sera) at 37°C for 1.5 hours, the pelleted clot was
discarded and then the remaining part was spun at 13200 rpm for 1 minute. The serum was
collected and stored at -20°C for further use. Animals were sacrificed on day twenty-eight
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and their spleens were removed. Half of the spleen was used to obtain single cell splenocyte
suspension and were incubated to compare IFNγ secretion between different treatment
groups and the rest of the spleen cells were used to generate total RNA and studied for the
expression of certain cytokines at mRNA level.
-1 0 13 14 27 28
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2. Control ODN + OVA
3. D3CG + OVA
4. Anionic Lipo(Control ODN+OVA)
5. Anionic  Lipo(D3CG+OVA)
•D3CG:15μg/mouse;
Control ODN: 15μg/mouse;
OVA: 7.5 μg/mouse;
•Free or liposome encapsulating above
adjuvant plus Ag were injected twice (d-1 &
d-14), IP, after bleeding. At the end of d-28
mice were sacked and spleens were
removed and studied for IFNγ and recall Ag
response.
•From Serums, anti-OVA Ig subtypes were
analysed by ELISA
•3 mice/group
Figure 6: The schedule of immunization protocol.
3.2.7. Fluorescence Activating Cell Sorting (FACS)
3.2.7.1. Cell Surface Marker Staining
Cells were centrifuged at 1500 rpm for 7 minutes at the end of the 24 hour incubation
period. Supernatant was sucked. The protocol was slightly modified from earlier studies
(Gursel et al. 2002; Gursel et al. 2006). Briefly, pellet was disturbed by using a pin rack
holder. If cells were to be stained and analyzed later, cells were fixed in 100 ml fixation
medium (Caltag, Austria) and transferred to 1.5 ml eppendorf tubes. Cells were incubated in
dark at room temperature for 15 minutes. 1 ml PBS-BSA-Na azide was added into each tube
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to wash cells. Cells were spun at 2000 rpm for 5 minutes. Supernatant was discarded and the
washing step was repeated. At the end of the second washing step, PBS-BSA-Na azide was
discarded and cells were incubated in fresh 50 ml PBS-BSA-Na azide containing 3 ml of
FITC-associated  monoclonal  antibody  against  CD86  (BD  Pharmingen).  If  cells  were  to  be
stained and analyzed immediately, fixation was not required. The cells can be stained in 50
ml PBS-BSA-Na azide containing 2-6 ml of fluorochrome-associated cell surface marker. The
remaining  steps  are  similar  but  all  steps  should  be  performed  on  ice  if  cells  are  not  fixed.
Cells were washed twice, resuspended in 500 ml  PBS-BSA-Na  azide,  transferred  to  FACS
tubes and analyzed in FACSCalibur (BD, USA).
3.2.8. Enzyme Linked Immunosorbent Assay (ELISA)
3.2.8.1. Cytokine ELISA
At the end of the incubation periods of cells stimulated in 96-well tissue culture
plates, plates were spun at 300xg for 6 minutes and 170 ml supernatant was collected from
each plate. Supernatants can be stored at -20°C. The ELISA protocol is a modified version
reported by Gursel, I, et al.(Gursel et al. 2003). Briefly, 96-well PolySorp plates (F96 Nunc-
Immunoplate,  NUNC, Germany) or Immulon 2HB plates (Thermo Labsystems, USA) were
coated with monoclonal antibodies against mouse cytokines IFNγ, IL-6 and IL4. 50 ml from
antibody solution (10 mg/ml for monoclonal antibodies against mouse IFNγ and IL-6) was
added to each well. Plates were incubated at room temperature for 5 hours or at 4°C for
overnight. Coating antibody was spilled. Wells were blocked with 200 ml blocking buffer for
2 h at room temperature. Plates were washed with ELISA wash buffer 5 times with 5 minute
incubation  intervals  after  each  wash  and  then  rinsed  with  ddH2O  for  3  times.  Plates  were
dried by tapping (same washing procedure was repeated in the subsequent steps).
Supernatants of cultured cells and recombinant proteins were added (50 ml/well from both).
Starting concentration for mouse IL6 and mouse IFNγ recombinant cytokines were
2000ng/ml and 500 ng/ml, respectively. Recombinant cytokines were serially two-fold
diluted serially with 50 ml 1X PBS. Plates were incubated for 2-3 hours at room temperature
or  overnight  at  4°C.  Plates  were  washed  as  explained  above.  Then,  50 ml from 0.5 mg/ml
biotinylated-secondary antibody solution (original biotinylated antibody stock was 1/1000
30
diluted in T-Cell Buffer, please see Appendix A for details) was added to each well. Plates
were incubated with biotinylated antibodies overnight at 4°C and were washed as previously
described. 50 ml from 1:2500 diluted streptavidin-alkaline phospahatase solution (SA-AP in
T-cell buffer must be prepared one day prior to its use and kept at 4°C) was added to each
well.  SA-AP was  further  incubated  for  1  hour  at  room temperature.  The  washing  step  was
repeated. 1 PNPP tablet was added to 4 ml ddH2O and 1 ml PNPP substrate for each plate
and 50 ml of PNPP substrate was added to each well. Yellow color formation was followed
and OD at 405 nm was analyzed with ELISA reader for several readings until recombinant
cytokine standards reach a four parameter saturation and S-shaped curve was obtained. Each
sample was layered as triplicate wells in order to obtain reproducible readings during the
study of each cytokine by ELISA. Average concentration for each group was determined by
the generated cytokine specific standard curve.
3.2.8.2. Anti-OVA IgG ELISA
IgG  ELISA  was  very  similar  to  cytokine  ELISA  except  for  a  few  steps.  All
incubation  times  and  washing  steps  are  similar  with  cytokine  ELISA  (please  see  above
section  for  details).  For  the  IgG  subclasses  instead  of  Immunlon  2HB,  Immulon  1B  plates
(Thermo Labsystems, USA) were used. Each well was coated with 50 ml of 10 mg/ml OVA
(Pierce, USA) diluted in 1X PBS. Blocking and washing steps are same as cytokine ELISA.
Instead of cell supernatants, mouse serum from each animal was layered on the first row in
1/7 titration (10 ml serum was diluted with 60 ml  1X PBS).  All  wells except for the 1st row
were pipetted with 52.5 ml, 1X PBS and 4-fold serial dilution was performed on vertical axis
by transferring 17.5 ml from above well to bottom well. Antibodies against mouse IgG, IgG1,
IgG2a, IgG2b were directly linked with alkaline phosphatase (AP). AP-linked IgG antibodies
(1 mg/ml) were 1:3000 diluted in T cell buffer and again prepared one day prior to their use.
After  the  addition  of  PNPP,  yellow  color  formation  was  followed  and  OD  at  405  nm  was
obtained with ELISA reader for several readings. Titrations at which similar ODs can be
observed were used to compare the level of IgGs between different treatment groups.
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3.2.9. Determination of gene expression at transcript level
3.2.9.1. Total RNA Isolation
Cells were centrifuged at 1500 rpm for 7 minutes at 4°C. Supernatant was discarded
and  cells  were  lysed  with  1  ml  Trizol,  a  mono-phasic  solution  of  phenol  and  guanidinium
thiocyanate (Invitrogen). Cell lysates can be stored at -80°C or can be transferred into 1.5 ml
eppendorf tubes for further RNA purification steps. All subsequent steps were performed on
ice  and  all  centrifugation  steps  were  done  at  4°C.  To  each  ml  of  Trizol  used,  200  µl
chloroform solution was added to each tubes and were immediately shaken vigorously for 15
seconds. After they were incubated at room temperature for 3 minutes, samples were
centrifuged at 13200 rpm for 15 minutes at 4°C. Following centrifugation, 550-600 µl of the
clear upper aqueous phase was transferred to a new eppendorf and 500 µl isopropanol was
added to each tube. The samples were gently inverted by up and down motion to allow
homogeneous mixing. Then, tubes were incubated at room temperature for 10 minutes and
centrifuged at 13200 rpm for 15 minutes. Supernatant was sucked and the pellet was gently
washed with 1 ml of 75% ethanol. Samples were centrifuged at 8000 rpm for 7 minutes.
Again, supernatant was discarded and pellet was gently washed with 1ml >99.9% ethanol.
After centrifugation at 8000 rpm for 7 minutes, ethanol was discarded and pellet was dried
under asceptic conditions under laminar flow hood in a tilted position. Dry pellets were
dissolved in 20 µl RNase/DNase free ddH2O. The OD measurements at 260 and 280 nm
wavelengths were obtained with the spectrophotometer NanoDrop® ND-1000 (NanoDrop
Technologies, USA). Purified total RNA samples were expected to have A260/A280 value
between 1.8 to 2.0 ratios which indicates minimal contamination with DNA, protein,
polysaccharides  or  phenol.  Samples  above  or  below  this  ratio  were  either  discarded  or
subjected to a repeated RNA purification procedure. All samples were stored at -80°C for
further use.
3.2.9.2. cDNA synthesis
cDNAs were synthesized from total RNA samples with the cDNA synthesis kit
(Finnzymes) according to the manufacturers’ protocol. 1µg total RNA was mixed with 1 µl
of Oligo (dT) 15-mer (100 ng)  primer and total volume was completed to 8 µl with RNase
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DNase free H2O in 0.2 ml PCR tubes. Tubes were pre-denatured at 65°C for 5 minutes in MJ
Mini thermocycler (BIO-RAD, USA) and then spinned down. 10µl RT Buffer (includes
dNTP mix and 10 mM MgCl2) and 2µl M-MuLV RNase H+ reverse transcriptase (includes
RNase inhibitor) were added to the mixture. Tubes were incubated at 25°C for 10 minutes,
40°C for 45 minutes and 85°C for 5 minutes. cDNA samples were stored at -20°C for further
use.
3.2.9.3. Semi-quantitative RT-PCR
Designed primers were developed with Primer3 Input v.0.4.0 program
(http://frodo.wi.mit.edu/primer3/input.htm) and Primer Designer Version 2.0 using the
cDNA sequences of human and mouse genes available at the EnsemblTM database. Each
primer pair was blasted (http://www.ncbi.nlm.nih.gov/BLAST/) against the mouse genome.
Other primer sequences were obtained from literature. All reagents were mixed and subjected
to optimal PCR conditions for specific primer set (Table 4) in MJ Mini thermocycler
(Biorad). PCR mixtures were prepared according to the protocol in Table 5. Running
conditions were given in Table 6. PCR products were kept at 4°C until they were loaded on
agarose gel.
Table 4: Mouse primer sequences
Primer Sequence Product Size
m b-actin Forward
Reverse
5’-GTATGCCTCGGTCGTACCA-3’
5’-CTTCTGCATCCTGTCAGCAA-3’
450 bp
m TLR-3 Forward
Reverse
5’-GGGGCTGTCTCACCTCCAC-3’
5’-GCGGGCCCGAAAACATCCTT-3’
250 bp
m TLR-7 Forward
Reverse
5’-TTAACCCACCAGACAAACCACAC-3’
5’-TAACAGCCACTATTTTCAAGCAGA-3’
700 bp
m TLR-9 Forward
Reverse
5’- GATGCCCACCGCTCCCGCTATGT-3’
5’-TGGGGTGGAGGGGCAGAGAATGAA-3’
430 bp
m TNF-α Forward
Reverse
5’-CCACCACGCTCTTCTGTCTAC-3’
5’-ACTCCAGCTGCTCCTCCACT-3’
189 bp
m IL-4 Forward
Reverse
5’-CCAAGGTGCTTCGCATATTT-3’
5’-TTTCAGTGATGTGGACTTGGAC-3’
161 bp
m IL-6 Forward
Reverse
5’-TGTGCAATGGCAATTCTGAT-3’
5’-CTCTGAAGGACTCTGGCTTTG-3’
226 bp
m IFNγ Forward
Reverse
5’-GCGTCATTGAATCACACCTG-3’
5’-ATCAGCAGCGACTCCTTTTC-3’
195 bp
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m IL-15 Forward
Reverse
5’-CATCCATCTCGTGCTACTTGTGTT-3’
5’-CATCTATCCAGTTGGCCTCTGT-3’
126 bp
m IL-18 Forward
Reverse
5’-GATCAAAGTGCCAGTGAACC-3’
5’-ACAAACCCTCCCCACCTAAC-3’
384 bp
m IP-10 Forward
Reverse
5’-GCCGTCATTTTCTGCCTCAT-3’
5’-GCTTCCCTATGGCCCTCATT-3’
127 bp
m CD40 Forward
Reverse
5’-GTCATCTGTGGTTTAAAGTCCCG-3’
5’-AGAGAAACACCCCGAAAATGG-3’
91 bp
mIFNα 6/8 Forward
Reverse
5’ TCAAGTGGCATAGATGTGGAAGAA 3’
5’ TGGCTCTGCAGGATTTTCATG 3’
384 bp
      Table 5: PCR Reagents
Reaction Ingredients Volume
2x DyNAzyme™ II PCR Master MixA 12,5 ml
DNAse/RNAse free  H2O 9 ml
Forward primer 1 ml (10pmol)
Reverse primer 1 ml (10pmol)
cDNA 1,5 ml
Total 25 ml
A 2x DyNAzyme™ II PCR Master Mix includes 0.04 U/μl DyNAzyme™ II DNA Polymerase, 20 mM
Tris-HCI (pH 8.8 at 25°C), 3  mM MgCl2, 100 mM KCl, stabilizers and 400 μM of each dNTP.
Table 6: PCR Conditions
Gene Names
PCR Steps
(Temp ; Time)
mTNFα,
mIFNγ,
mIL15,
mIL6
mCD40
mβactin,
mIL18,
mIP10,
mTLR3,
mTLR7
mIFNα 6/8,
mTLR9
Initial
Denaturation
- 95°C ; 3’’ - 94°C ; 2’
Denaturation 94°C ; 30’’ 95°C ; 30’ 94°C ; 30’’ 94°C ; 30’’
Annealing 60°C ; 30’’ 62°C ; 30’ 55°C ; 30’’ 64,3°C ; 30’’
Extension 72°C ; 30’’ 72°C ; 45’ 72°C ; 30’’ 72°C ; 1’
Repeat (Cycle #) 40 34 34 40
Final Extension 72°C ; 5’ 72°C ; 7’ 72°C ; 5’ 72°C ; 10’
’ denotes mins; ’’ denotes secs
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3.2.9.4. Agarose gel electrophoresis and quantification of band intensities
1.5%  agarose  gel  was  prepared  with  1X  TAE  buffer  and  final  concentration  of
ethidium bromide was 1 mg/ml. 2 ml loading dye was mixed with 10 ml PCR product. 10 ml of
mixture was loaded to each well. 5 ml of 105 ng/μl DNA ladder with 100-1000bp range or
low range DNA ladder with 50-1000bp range (Jena Biosciences) was loaded on an empty
well and used as a marker. 100V is applied for 45 minutes and the gel was visualized under
UV transilluminator (Vilber Lourmat, France). The gel exposure time was kept fixed at 0.1
second for each run. Band intensity analysis was performed with BIO-PROFILE Bio-1D
V11.9 sofware. Band intensity for each product was measured and background intensity was
subtracted from this value. Blanked intensities for each product were divided by blanked
house-keeping gene (β-actin) values to normalize resulting quantitative data or directly
compared.
3.2.10. Statistical Analysis
Statistical analysis was performed in SigmaSTAT 3.5 software. Student’s t-test was
used to understand if differences between untreated groups, groups treated with control-
ODNs and ODN-treated groups were statistically significant.
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4. RESULTS
4.1. Studies to reveal the most potent immunostimulatory ODN-liposome formulation
Modulating the immunostimulatory activities of TLR ligands is critical to design
effective vaccine adjuvants. Previous studies have shown that nucleic acid-based intracellular
TLR ligands are very labile and their immunostimulatory activity can be enhanced by
encapsulating them into liposomes (Barry et al. 1999; Gursel et al. 2001). For this, five
different types of liposomes varying in size, lamellarity and surface net charge was prepared
as mentioned in Materials and Methods section. These TLR ligands were encapsulated either
alone or with their 1:1 combinations into these liposomes.  Our first effort was to determine
which liposome type encapsulated which TLR ligand at the highest efficiency, since this will
be correlated with the improved cytokine response following splenocyte stimulation ex vivo.
The cytokine responses from splenocytes were determined by ELISA and RT-PCR (plese see
below sections).
4.1.1. Determining the liposome encapsulation efficiency
Due to different physicochemical characteristics of liposomes, their ability to
encapsulate different nucleic acid based ligands was expected to vary. After the liposomes
were spun down from PBS solution where the liposomes were suspended in, the
concentration of ODNs in the solution (i.e. unencapsulated fraction) was determined by UV
spectroscopy (NanoDrop®). As the total amount of ODNs initally mixed with the SUV
before  the  encapsulation  step  was  known  (1.0  mg  CpG  or  pIC  was  mixed  with  20  µmole
lipid), it was possible to calculate the amount of ODN entrapped within the liposomes. The
Table 7 summarizes the percent ODN encapsulation within different liposomes as well as
controlled release profiles from different formulations. It was already established that the
ability of positively charged liposomes to encapsulate ODN is far better than neutral, stealth
or negatively charged liposomes (Gursel et al. 2001). The reason for improved entrapment in
cationic liposomes is due to the strong electrostatic interaction between positively charged
cationic lipid with negatively charged ODNs.
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Table 7: The encapsulation efficiency and ODN release of K and D-type ODN encapsulating liposomes.
Liposome
Type
K-Type ODN
Loading (%)A
D-Type ODN
Loading (%)
Percent ODN Released Over TimeB
(D and K-Type averaged)
12h 1d 2d 4d 8d
Neutral 67.4±5.6 84.9±3.3 5.3±3.3 7.7±4.7 12.7±3.3 13.1±4.2 21.7±5.7
Anionic 71.5±4.2 89.5±4.6 12.5±2.9 19.6±3.8 23.5±7.2 32.5±3.0 40.2±5.1
Cationic 93.1±7.7 97.1±2.4 3.1±1.7 5.1±0.7 8.1±2.8 15.1±3.6 20.1±6.1
Stealth 78.9±2.0 88.9±3.8 8.9±2.0 10.8±3.3 14.9±3.1 16.1±2.6 18.9±3.8
SSCL 85.4±11.2 98.7±3.5 2.4±1.2 5.4±1.7 7.4±2.2 10.1±1.2 13.9±4.2
All ODN measurements were done using 1555 (K-Type) and D35 (D-Type) CpG ODNs, run in triplicates
from at least three independent liposome preparations are reported. Data represents Ave ± SEM.
A OD260nm from supernatants were used to calculate loading efficiencies after obtaining the liposome
pellet.
B Release of ODN @ 37°C into PBS was followed by OD readings from supernatants after obtaining the
liposome pellet.
The ODN encapsulation efficiency with D-type CpG was much higher than that of K-
Type regardless of different liposome preparations (see Table 7, left panels). As seen in
Table 7, liposomes were assayed for duration of 7d and ODN release was followed every 12h
intervals. Three different liposome types gave ~20% release of their cargo at the end of one
week. However, the lowest release level was seen with SSCL liposomes (13.9±4.2) and
anionic liposomes gave the highest ODN release (40.2±5.1), meaning SSCL are the most
stable and anionic is the least stable to retain ODN.
The storage stability (i.e. shelf-life) is critical for liposome formulations. We have
investigated the storage stability of these liposomes five months after their production date.
The more a liposome is stable the more it retains its cargo.
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Table 8: Percent encapsulation of different type of CpG ODNs encapsulated or coencapsulated with pIC
in 5 types of liposomes following five month of storage in the fridge.
1555 K23 1612 D35 I-127 K23+pIC D3CG+pIC I-127+pIC
Neutral 12.8 0   3.2 84.6 58.0 0 0 38.0
Anionic 23.0 0 24.0 82.7 58.0 0 0 0
Cationic 95.0 75.0 79.6 97.9 92.8 70,6 82,4 92.2
Stealth   8.6 N.D 40.8 85.4 N.D N.D N.D N.D
SSCL 95.1 84.8 85.6 98.3 95.0 89.8 87.3 92.4
N.D. not determined
As summarized in Table 8, the encapsulation efficiency measurements 5 months after
the production date revealed that SSCL and cationic liposomes are quite stable upon storage
at 4°C.  Regardless of the type of the nucleic acid TLR ligands used during liposome
preparation,  SSCL  retained  over  85%  and  cationic  over  70%  of  its  cargo  at  the  end  of  5
months. Strikingly, D35 encapsulating liposomes (regardless of their properties) held over
80% of the initial input amount at the end of this storage period (please check lane 4 with
others, Table 8).
4.1.2. Cytokine ELISA after in vitro stimulations of splenocytes with K-ODN and D-
ODN encapsulating liposomes.
In order to understand the cytokine secretion profile upon stimulation with TLR
ligand encapsulating liposomes we collected supernatants of spleen cell cultures after 36
hours of incubation. IL6 and IFNγ levels were checked by ELISA.  Initial studies were done
with 1555 ODN. When CpG ODN 1555 is encapsulated into cationic and SSCL liposomes it
induced approximately 20 and 100 ng/ml IFNγ, while no IFNγ secretion could be detected
upon stimulation with free ODN at lowest dose (0.3μM) (Figure 8). Similarly, but
specifically at low ODN concentration, IL6 response is augmented by 3 fold when 1555 is
encapsulated into SSCL liposome (a rise from 90±16.4 to 266.8±23.8 ng/ml) (Figure 7).
These activations were strictly CpG motif specific. When Control ODNs were encapsulated
or empty liposomes themselves were treated with spleen cells, no appreciable amounts of
IFNγ or  IL6  was  detected  from their  cell  supernatants  which  is  a  strong  indication  that  the
observed immunogenicity is CpG motif dependent (Figure 13 and Figure 14).
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The heterogenicity in liposome/1555 response was observed. When 1555 is loaded
within neutral, stealth and anionic liposomes it substantially lost its stimulatory activity.
(Figure 7 and Figure 8)
Stimulation with various D35-liposome complexes also yielded heterogeneous
responses. Results indicated that IFNγ and IL6 production from mouse splenocytes were
significantly increased when D-type ODN was encapsulated in neutral, anionic, or stealth
liposomes. Surprisingly, and contrary to what we have observed for 1555 ODN, D-ODN
activity was completely lost when loaded within vesicles where positively charged lipid is
included in the formulation (Figure 11 and Figure 12).
Alternative design of K-ODN, K23, was also tested throughout this study. Of note,
the most distinguishable features of K23 from 1555 are, K23 is shorter (12mer vs 15mer) and
it contains two CpG motifs in its sequence whereas 1555 is 15-mer and has only one CpG
motif. To our surprise, following stimulation with K23-liposome formulations, the cytokine
production  levels  (IFNγ and  IL6)  from  spleen  cells,  resembled  more  to  D-Type  ODN-
liposome complex stimulations rather than 1555-liposome formulation stimulations. At the
lowest dose of K23 (0.3μM) that is encapsulated into neutral and anionic liposomes, 3 fold
more IL6 was induced (Figure 9).  Although free K23 could not stimulate any detectable
IFNγ secretion, K23 encapsulated within neutral and anionic liposome induced
approximately 5 and 10 fold more IFNγ secretion. Considering the lowest stimulation dose,
while 1555 induces the strongest IFNγ and IL6 secretion when they are encapsulated into
SSCL liposome, K23 and D35 yielded robust proinflammatory cytokine responses in either
anionic or neutral liposomes. As the dose of K23 increased, the IFNγ secretion increased
correspondingly (Figure 10).
 The substantial loss of IFNγ secretion with certain liposomes encapsulating CpG
ODNs (D or K-Types), prompted us to determine whether a Th2-dominant cytokine secretion
is mediating these suppressions. Earlier studies reported that IL4 (a Th2-biased cytokine) is
the cardinal cytokine that can suppress IFNγ production (Tanaka et al. 1993). To rule out this
possibility, we have checked IL4 levels from the liposome encapsulating K- or D-type ODN
treated mouse spleen cells and found out that there was no detectable IL4 from these sups
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(data not shown). This finding implied that the suppression was not due to a Th1 to Th2 shift
in immunity (that is mediated by different liposome types). Collectively these results indicate
that K-ODN and D-ODN induces differential cytokine production when they are
encapsulated into liposomes with different physicochemical characteristics.
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Figure 7: Dose-dependent IL6 production from splenocytes following 36 hours of stimulation
with free (No Lipo) or various liposomes encapsulating 1555 (0.3-3.0 μM), IL6 production by
splenocytes was detected from cell supernatants by ELISA. Experiment samples were run in
triplicates and results are reported as the average of at least two independent studies. Results
(mean concentration ± SEM) are combination of two independent experiments. p<0.001 for
0.3μM and 1μM, p=NS for 3μM (SSCL vs No Lipo paired t-test analyses comparisons).
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Figure 8: IFNγ production from splenocytes following stimulation with free (No Lipo) or various
liposomes encapsulating 1555. IFNγ production by splenocytes was detected from cell
supernatants by ELISA. Experiment samples were run in triplicates and results are reported as the
average of at least two independent studies. p<0.01 for 0.3 and 1μM (Cationic vs No Lipo) and
p<0.0001 for 0.3 and 1μM (SSCL vs No Lipo, paired t-test analyses comparisons).
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Figure 9: Dose-dependent IL6 production from splenocytes following stimulation with free (No
Lipo) or various liposomes encapsulating K23. (For more information please see Figure 7 legend)
p<0.001  for  0.3μM, 1μM and  3μM (Neutral  vs  No  Lipo  and  Anionic  vs  No  Lipo  paired  t-test
analyses comparisons). **; not determined.
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Figure 10: IFNγ production from splenocytes following stimulation with free (No Lipo) or
various liposomes encapsulating K23. p<0.01 for 0.3 μM (Neutral vs No Lipo and Anionic vs No
Lipo) and p<0.0001 for 1μM  and for 3 μM (Neutral vs No Lipo and Anionic vs No Lipo paired t-
test analyses comparisons).  **; not determined, *; not detectable. (For more information please
see Figure 8 legend)
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Figure 11: Dose dependent IL6 production from splenocytes following stimulation with free (No
Lipo) or various liposomes encapsulating D35 (For more information please see Figure 7 legend).
p<0.001 for  0.3μM, and 1μM (Neutral  vs  No Lipo,  Anionic vs  No Lipo and SSCL vs No Lipo
paired t-test analyses comparisons).
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Figure 12: IFNγ production from splenocytes following stimulation with free (No Lipo) or
various liposomes encapsulating D35. (For more information please see Figure 8 legend) p=0.06
for 0.3μM, p<0.001 for 1μM and 3μM (Neutral and Anionic vs No Lipo paired t-test analyses as
well as SSCL vs No Lipo for 3 μM analyses comparisons). Cationic and SSCL vs No Lipo t-test
was NS
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Figure 13: IL6 production from splenocytes following stimulation with 0,86μM liposomes that do
not encapsulate any TLR ligand, 5μg/ml PGN and 5μg/ml LPS as positive control (For more
information please see Figure 7 legend) *; not detectable.
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Figure 14:  IFNγ production from splenocytes following stimulation with 0,86μM liposomes that
do not encapsulate any TLR ligand, 5μg/ml PGN and 5μg/ml LPS as positive control (For more
information please see Figure 8 legend) *; not detectable.
Table 9: Summary of relative IL6 secretion induction following stimulation with 0.3μM free or
various liposomes encapsulating 1555, K23 and D35.
1555 K23 D35
No Lipo + + 0
Neutral + ++ ++++
Anionic + ++ ++++
Cationic + + ++
Stealth + N.D ++++
SSCL ++ 0 +
Lowest doses were considered. If stimulation with free ODN (No Lipo) yielded IL6 response, the
amount of IL6 was marked as “+” and relative IL6 secretion inductions was calculated
according to “No Lipo” group. In this case “No Lipo” is the reference group. If “No Lipo”
stimulation did not yield any IL6 response, “No Lipo” group was shown as “0”. Then the group
that yielded lowest amount of IL6 secretion was denoted as “+” and relative IL6 secretion
inductions were calculated according to that reference group. 0; no induction, +;  <2 fold
induction compared to reference group or, ++; between 2-3 fold induction, +++; 3-4 fold
induction, ++++; 4< fold induction, N.D; not determined.
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Table 10: Summary of relative IFNγ secretion induction following stimulation with 0.3μM free or
various liposomes encapsulating 1555, K23 or D35
1555 K23 D35
No Lipo 0 0 +
Neutral 0 ++ ++++
Anionic 0 ++++ ++++
Cationic + + +
Stealth 0 N.D +
SSCL ++++ 0 +
Lowest doses were considered. If stimulation with free ODN (No Lipo) yielded IFNγ response, the
amount of IFNγ was marked as “+” and relative IFNγ secretion inductions was calculated
according to “No Lipo” group. In this case “No Lipo” is the reference group. If “No Lipo”
stimulation did not yield any IFNγ response, “No Lipo” group was shown as “0”. Then the group
that yielded lowest amount of IFNγ secretion was denoted as “+” and relative IFNγ secretion
inductions were calculated according to that reference group. 0; no induction, +;  <2 fold
induction compared to reference group or, ++; between 2-3 fold induction, +++; 3-4 fold
induction, ++++; 4< fold induction, N.D; not determined.
 The global modification in cytokine production following liposome encapsulation
of various K or D-Type ODNs is summarized in Table 9 and Table 10. These tables clearly
demonstrate that when different ODN classes encapsulated within different liposomes
induces differential cytokine secretion from innate immune cells.
4.1.3. Effect of liposome encapsulated D-ODN or K-ODN on cytokine transcript
levels.
When one of the aims of ODN incorporation within a depot system is to augment its
immuno adjuvant effect, it is of great importance to detect the breadth of activation with
these delivery systems. While IFNγ is a very vital cytokine to regulate and mount Th1
dominant cell-mediated immune response, IFNα is a very critical cytokine modulating anti-
viral immunity. We have speculated that positively charged liposomes could alter subcellular
localization  of  D-ODN and thus  prevent  it  to  signal  from early  endosome through MyD88
and IRF7. One way of analyzing this effect is to use intracellular IFNα cytokine staining by
flow cytometry and another powerful approach is to use conventional ELISA. Unfortunately,
none of these reagents for mouse is available at hand, thus we shifted our detection strategy
45
to  PCR.  For  this,  mouse  spleen  cells  were  stimulated  for  1  or  8  hours,  and  total  RNA was
purified, and specific gene transcripts were studied by RT-PCR. As seen in Figure 15 and
Figure 16a, eight hours after stimulations, spleen cells treated with neutral, anionic and
stealth liposomes encapsulating D35 gave higher IFNα mRNA levels than positively charged
liposomes encapsulating D35.  As expected, 1555 did not induce any IFNα transcripts. These
results indicate that positively charged liposomes interfere with D-ODN recognition by
TLR9.
We could  not  detect  difference  in  transcript  levels  of  CD40 and  IL18 at  either  time
points following CpG ODN-liposome complex stimulation compared to untreated or with
free ODN stimulation groups (Figure 15 and Figure 16b,c), these data collectively indicated
that liposomes do not alter signaling mechanisms of these cytokines.
Control ODN 1555 D35
IL18 1h
IL18 8h
IFNα 1h
IFNα 8h
CD40 1h
CD40 8h
β-actin 1h
β -actin 8h
Figure 15: PCR results that was performed from total RNA of splenocytes following stimulation
with free (No Lipo) or various liposomes encapsulating 1μM control ODN, 1555 and D35.
5μg/ml PGN and LPS were used as positive control.
46
0,000
0,050
0,100
0,150
0,200
0,250
0,300
0,350
0,400
0,450
0,500
N
aï
ve
PG
N
LP
S
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
aï
ve
PG
N
LP
S
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
Control ODN 1555 D35 Control ODN 1555 D35
1 hour 8 hours
0,000
0,200
0,400
0,600
0,800
1,000
1,200
N
aï
ve
PG
N
LP
S
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
aï
ve
PG
N
LP
S
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
Control ODN 1555 D35 Control ODN 1555 D35
1 hour 8 hours
0,000
0,500
1,000
1,500
2,000
2,500
3,000
N
aï
ve
PG
N
LP
S
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
aï
ve
PG
N
LP
S
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
N
o 
Li
po
N
eu
tr
al
A
ni
on
ic
Ca
tio
ni
c
St
ea
lth
SS
CL
Control ODN 1555 D35 Control ODN 1555 D35
1 hour 8 hours
O
D
 V
al
ue
a IFNα
b CD40
c IL18
Figure 16: Density measurements of the gel electrophoresis picture in Figure 15 for IFNα (a),
CD40 (b) and IL18 (c). Density measurement values of genes were normalized according to β-
actin as housekeeping gene by dividing density value of gene to density value of β-actin.
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4.1.4. Cytokine ELISA after in vitro stimulations of splenocytes with liposomes
encapsulating pIC
Among nucleic acid TLR ligands, in addition to CpG DNA, dsRNA (such as
synthetic pIC) triggers signaling cascade through TLR3 and is one of the strong candidates
for clinical applications. Similar to CpG ODN, pIC is a very labile molecule and attains
considerable efforts to improve its in vivo activity. We checked whether liposome
encapsulating pIC offers an advantage to its free counterpart. We have checked whether we
can improve cytokine production of pIC by achieving liposome encapsulation.
 While 22.5μg/ml concentration of free pIC could only induce barely detectable
amount of IFNγ (2ng/ml) and dose dependent substantial IL6 secretion, encapsulating pIC
into neutral, anionic, cationic and stealth liposomes induced significantly high IFNγ (even at
the lowest 2.5μg/ml dose where free pIC fail to induce any cytokine production) (Figure 17
and Figure 18)
The improved IFNγ with low dose stimulation is critical. When these formulations
are injected in vivo, due to fast dilution and premature clearance by absorption onto serum
proteins may facilitate ineffective accumulation and internalization level of free dsRNA
leading to ineffective in vivo performance. Liposome encapsulation is a very potent tool to
overcome this problem and thus, significantly improve the immunostimulatory activity. Data
in Figure 17 and Figure 18 strongly indicate that at low dose stimulation with liposome
formulations except SSCL are very strong cytokine inducers (from no induction to 350 ng/ml
IFNγ with anionic liposome encapsulating pIC). At higher doses of pIC, anionic liposome
induced 425ng/ml as opposed to 2ng/ml free pIC. Similarly, neutral liposomes followed the
same trend. (Figure 18)
As seen in Figure 18, liposomal pIC induced substantially higher levels of IL6 for all
tested liposome types, except SSCL, at all concentrations. Among all liposome types, anionic
and stealth liposome encapsulating pIC gave the highest activity. Approximately, a 9 fold
more induction was observed at 2.5μg/ml dose (from 30±8 to 265±31 μg/ml for pIC and
anionic liposomal pIC, respectively), and at 22.5 μg/ml this trend was still retained (50±7 to
389±29 ng/ml) (Figure 17).
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Figure 17:  IL6 production from splenocytes following stimulation with free (No Lipo) various
liposomes encapsulating pIC. (For more information please see Figure 7 legend) p<0.001 for
0.3μM, 1μM and 3μM (Neutral, Anionic, Cationic and Stealth vs No Lipo paired t-test analysis
comparison). For SSCL vs No Lipo group analyses: p=0.002 at 2.5μg/ml and 22.5μg/ml, at
7.5μg/ml, p=0.03.
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Figure 18:  IFNγ production from splenocytes following stimulation with free (No Lipo) or
various liposomes encapsulating pIC. (For more information please see Figure 8 legend). p<0.001
for  0.3μM, 1μM and  3μM (All  groups  vs  No  Lipo  paired  t-test  analysis  comparison).  At  3μM
SSCL is NS
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4.1.5. Effect of various liposomes encapsulating pIC on transcript level
As mentioned above, dsRNA serve as activator of innate immune cells that induce
both type I IFNs and Th1 type immune response via a TRIF dependent signaling pathways.
IFNα, a cardinal cytokine against anti-viral immunity is also contributing to the Th1
development. We have studied to reveal whether liposome encapsulation of either pIC alone
or co-encapsulation with D-ODN improves IFNα message levels. In addition to IFNα, a co-
stimulatory molecule CD40 and another Th1 related critical cytokine IL18 message from
spleen cells were assessed by RT-PCR.
We have stimulated splenocytes for one and 8 hours with free or various forms of
liposomes encapsulating pIC (5μg/ml). At the end of first hour, we detected basal level of
IFNα and CD40 mRNA levels which is similar with untreated (naïve) group (Figure 19 and
Figure 20a, b). The differential response for IL18 could be observed at the first hour.
Although free pIC did not increased IL18 mRNA level, neutral and cationic liposome
encapsulating pIC increased the transcript level approximately 1.5 fold. Interestingly pIC in
the stealth liposome decreased the IL18 mRNA amount (Figure 19 and Figure 20c).
When pIC was loaded in stealth liposome, we have observed significant amount of
IFNγ response (Figure 18). This observation is very puzzling, since IL18 is known to
promote IFNγ production (Dinarello et al. 2003) our data imply that IFNγ induction via pIC
encapsulating liposome is IL18 independent.
At the end of eighth hours of stimulation, cells stimulated with pIC encapsulating
neutral or stealth liposome induced a 4 fold and an 11 fold increase in IFNα message
compared to free pIC stimulation (Figure 19 and Figure 20a). Compared to 1h mRNA
response,  there  was  no  change  in  the  IL18  and  CD40  transcript  levels  at  the  end  of  8h  of
stimulation (Figure 19 and Figure 20b and c). IFNα response observed in naive group at the
end  of  8th hour of stimulation is probably due to contamination happened in that group.
Additionally,  every  β-actin  band,  which  was  used  for  normalizations,  does  not  possess  the
same optical density. That’s why we obtained a deceptive bar showing presence of IFNα
transcript as much as obtained from stealth-pIC stimulation (Figure 19a).
Collectively  these  data  suggests  that  IFNα message  of  pIC is  augmented  when it  is
encapsulated in either stealth or neutral liposomes. Besides IFNγ induction by pIC
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encapsulating stealth liposome is independent of IL18 but cationic liposomes encapsulating
pIC dependent IFNγ could be IL18 dependent.
pIC
IL18 1h
IL18 8h
IFNα 1h
IFNα 8h
CD40 1h
CD40 8h
βactin 1h
βactin 8h
Figure 19: PCR results that were performed from total RNA of splenocytes following stimulation
with free (No Lipo) or various liposomes encapsulating 5μg/ml pIC. 5μg/ml PGN and LPS were
used as positive control.
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Figure 20: OD measurement results of the gel electrophoresis picture in Figure 19 for IFNα (a),
CD40 (b) and IL18 (c). Density measurement values of genes were normalized according to β-
actin as housekeeping gene by dividing density value of gene to density value of β-actin.
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4.2. Studies to understand whether coencapsulating endosomal TLR ligands into
liposomes induces a more pronounced activation
4.2.1. Cytokine ELISA after in vitro stimulations of splenocytes with liposomes
coencapsulating K-ODN or D-ODN and pIC
Previous  studies  demonstrated  that  D class  of  CpG ODN (D-Type)  is  also  a  strong
inducer of IFNα (Gursel et al. 2006). Next we have checked if we can augment effect of pIC
by coencapsulating with CpG ODN into liposomes. Here, K23 and D3CG have been
coencapsulated with pIC separately. Even though there was a slight increase in the IL6
secretion when K23 is coencapsulated with pIC in anionic liposome, this secretion was
insignificant. However, IFNγ secretion was induced remarkably when K23 and pIC was
coencapsulated both in anionic and SSCL liposome. Here it is important to note that at the
lowest doses of free K23 and pIC yielded fairly low detectable amount of IFNγ (Figure 21
and Figure 22). These data revealed that when K23 and pIC is coencapsulated in anionic
liposome, it synergistically induced strong IFNγ response.
D-Type ODN plus pIC in neutral or anionic liposomes boosted both IL6 and IFNγ by
about 6 fold (this increase is more prominent at low doses). Surprisingly, IFNγ and IL6
secretions were suppressed at all tested doses when pIC and D3CG were loaded into cationic
and SSCL liposomes (Figure 23 and Figure 24). These data suggest that in neutral or anionic
liposome, pIC and D3CG showed stronger synergistic activity however when they are
coencapsulated into positively charged liposomes (Cationic or SSCL), probably due to
simultaneous signaling mechanisms of TLR3 and TLR9 antagonizes with each other and
yield very low cytokine secretion. Collectively these findings implicated that coencapsulating
TLR3 and TLR9 ligands in anionic liposome yielded the strongest Th1 type cytokine
production.
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Figure 21 :  IL6 production from splenocytes following stimulation with free (No Lipo) or
various liposomes coencapsulating K23 and pIC (0.3-3μM and 2.5-22.5μg/ml respectively), (For
more information please see Figure 7 legend).
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Figure 22: IFNγ production from splenocytes following stimulation with free (No Lipo) or
various liposomes coencapsulating K23 and pIC (0.3-3μM and 2.5-22.5μg/ml respectively). (For
more information please see Figure 8 legend).   p<0.01 for  0.3μM, 1μM and 3μM of SSCL and
Neutral  vs  No Lipo.  For  Anionic vs  No Lipo t-test  analyses,  p<0.001 at  all  concentrations.  For
cationic group comparison: at first dose p=NS, second and third doses p<0.01.
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Figure 23: IL6 production from splenocytes following stimulation with free (No Lipo) or various
liposomes coencapsulating D3CG and pIC (0.3-3μM and 4-36μg/ml respectively). (For more
information please see Figure 7 legend).  For Neutral vs No Lipo and Anionic vs No Lipo p<0.01
at the first 2 doses. The highest dose is NS. Cationic and SSCL groups comparisons to that of No
lipo at all concentrations are NS.
0
50
100
150
200
250
300
350
400
No Lipo Neutral Anionic Cationic Stealth SSCL
IF
N
γ
(n
g/
m
l)
(0.3μM+4μg/ml)
(1μM+12μg/ml)
(3μM+36μg/ml)
* **
Figure 24: IFNγ production from splenocytes following stimulation with free (No Lipo) or
various liposomes coencapsulating D3CG and pIC (0.3-3μM and 4-36μg/ml respectively). (For
more information please see Figure 8 legend). For Neutral and Anionic vs No Lipo p<0.001 at the
second doses. Anionic vs No Lipo, first dose is p<0.01, and the rest of the t-test analyses between
groups are NS.
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Table 11: Summary of relative IL6 secretion induction following stimulation with free or various
liposomes encapsulating pIC, K23+pIC and D3CG+pIC at lowest doses
K23 D35 pIC K23+pIC D3CG+pIC
No Lipo + 0 + + +
Neutral ++ ++++ ++++ + ++++
Anionic ++ ++++ ++++ + ++++
Cationic + ++ ++++ + ++
Stealth N.D ++++ ++++ N.D N.D
SSCL 0 + +++ 0 +
Lowest doses were considered. If stimulation with free ODN (No Lipo) yielded IL6 response, the
amount of IL6 was marked as “+” and relative IL6 secretion inductions was calculated
according to “No Lipo” group. In this case “No Lipo” is the reference group. If “No Lipo”
stimulation did not yield any IL6 response, “No Lipo” group was shown as “0”. Then the group
that yielded lowest amount of IL6 secretion was denoted as “+” and relative IL6 secretion
inductions were calculated according to that reference group. 0; no induction, +; observed
induction at reference group or <2 fold induction, ++; between 2-3 fold induction, +++; 3-4 fold
induction, ++++; 4< fold induction,
Table 12: Summary of relative IFNγ secretion induction following stimulation with free or
various liposomes encapsulating pIC, K23+pIC and D3CG+pIC at lowest doses.
K23 D35 pIC K23+pIC D3CG+pIC
No Lipo 0 + 0 + +
Neutral ++ ++++ +++ ++ +
Anionic ++++ ++++ ++++ ++++ ++++
Cationic + + +++ + 0
Stealth N.D + ++++ N.D N.D
SSCL 0 + + +++ +
Lowest doses were considered. If stimulation with free ODN (No Lipo) yielded IFNγ response, the
amount of IFNγ was marked as “+” and relative IFNγ secretion inductions was calculated
according to “No Lipo” group. In this case “No Lipo” is the reference group. If “No Lipo”
stimulation did not yield any IFNγ response, “No Lipo” group was shown as “0”. Then the group
that yielded lowest amount of IFNγ secretion was denoted as “+” and relative IFNγ secretion
inductions were calculated according to that reference group. 0; no induction, +; observed
induction at reference group or <2 fold induction, ++; between 2-3 fold induction, +++; 3-4 fold
induction, ++++;4 < fold induction.
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4.2.2. Effect of various liposomes coencapsulating CpG and pIC on IFNα, CD40,
IL15 and IL18 transcript levels.
Firstly we have checked IFNα transcript levels to reveal whether liposome
coencapsulation of pIC together with D3CG (alternative design of D-ODN) or K23 can
increase IFNα transcript levels. Although we do not expect any IFNα response at the end of
1h of stimulation (IFNα production is under positive feedback of its own production, so 1h is
too early for such kind of effect) we have detected small increase in the message level in all
liposome types tested. At the end of 8h free D3CG+pIC (1μM+3,6μg/ml) showed a slight
IFNα message.  Consistent with previous observation regarding IFNγ and IL6 production by
ELISA (please see Figure 23 and Figure 24 ) positively charged liposomes coencapsulating
D3CG + pIC yielded a substantial lost (compared to unencapsulated counterparts) in IFNα
transcript level. Neutral and anionic liposomes induced about 4-5 fold higher IFNα message
(Figure 25 and Figure 26a). It is known that K-ODN does not lead to any detectable IFNα
from human PBMC (Gursel et al. 2002). Similar to that observation, we did not observe any
IFNα message induction with any liposome types tested with coencapsulating K23 and pIC
(Figure 25 and Figure 26).
 At the end of 1h, CD40 transcript levels did not change upon stimulation with all
liposomal types. At the end of eighth hour of stimulation, cells that were stimulated with
K23+pIC coencapsulating liposomes showed higher amount of CD40 mRNA compared to
free form. The trend with K-ODN is reversed when D3CG + pIC message either in neutral or
in anionic liposomes was investigated over time. There is an augmentation in CD40 message
by 1h post-treatment and the augmentation is lost by the end of 8h (Figure 25 and Figure
26b).
IL15 mRNA levels both with pIC plus K or D-type liposomal formulations increased
at eighth hour of stimulation. The exception with this cytokine is the cationic liposome
coencapsulating D3CG and pIC. At 1h, none of the liposomal formulations of pIC and K23
(or D3CG) altered IL18 levels significantly (Figure 25 and Figure 26c and d). By 8h, from
anionic (K+pIC) and cationic (D+pIC) liposome types, message reduction is observed.
Collectively these data reveals us that when pIC and D-ODN is coencapsulated into
neutral  or  anionic  liposome,  we  can  obtain  very  strong  Type  I  IFN  cytokine  response
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together with augmented CD40 levels. These responses would increase protection against
viral infections in vivo.
IFNα 1h
IFNα 8h
βactin 1h
βactin 8h
K23+polyIC D3CG+polyIC
CD40 8h
CD40 1h
IL15 1h
IL15 8h
IL18 8h
IL18 1h
Figure 25: PCR results that were performed from total RNA of splenocytes following stimulation
with various liposomes coencapsulating or free 1μM K23 or D3CG and 3.6μg/ml or 6μg/ml pIC
respectively. 3,6μg/ml free pIC, 1μM free D3CG and 1μM free K23 were used as control groups.
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Figure 26: OD measurement results of the gel electrophoresis picture in Figure 25 for IFNα (a),
CD40 (b), IL15 (c) and IL18 (d). Density measurement values of genes were normalized
according to β-actin as housekeeping gene by dividing density value of gene to density value of
β-actin.
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4.3. Detection of activated APCs upon stimulation with nucleotide encapsulating
liposomes
A naive T cell requires a second signal to proliferate and differentiate into effector T
cells following encountering with an antigen. This second signal is known as co-stimulation.
Co-stimulation is mediated by costimulatory molecules, such as B7-1 (CD80) and B7-2
(CD86) expressed on mouse APCs including DCs, macrophages and B cells. The CD86 is
expressed constitutively at low levels on APCs and its upregulation is initiated upon
recognition either by PAMPs (i.e. through TLRs) or exposure to inflammatory cytokines
such as IFNγ, IL12 or IL6. Of note, the CD80 upregulation requires longer exposure and may
take days (Greenwald et al. 2005; Abbas et al. 2007). We decided to investigate the
activation ability (by CD86 staining) of APCs by liposomes encapsulating or coencapsulating
TLR3 and TLR9 ligands.
Results of CD86 staining are not supporting our previous IL6 and IFNγ ELISA data.
For instance, 14% of splenocyte population that was stimulated with cationic liposome
loaded with D35 was positive for CD86 (Figure 27).
A similar trend is valid for stimulations with D3CG plus pIC liposomes. Based on our
previous experience, we were expecting to obtain the highest activation profile by neutral and
anionic liposomes, contrary to our expectation, cationic and SSCL liposome yielded the
highest CD86 upregulation. CD86 upregulation using pIC encapsulating liposomes in general
gave  very  low  activation  except  for  SSCL  type  (ca.  3  fold  over  untreated  naive  group)
(Figure 27).
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Figure 27: Percentage of CD86 expressing splenocytes upon stimulation for 4 hours with various
liposomes encapsulating or free 1μM D35, 3μg/ml pIC or coencapsulated 1μM D3CG and 3μg/ml
pIC. 1 μM free I-127, neutral liposome encapsulating or coencapsulated with 3μg/ml pIC and
5μg/ml PGN were used as control groups.
4.4. In vivo studies utilizing nucleic acid TLR ligands encapsulated in different
liposome formulations
As our  aim is  to  design  a  strong  vaccine  adjuvant,  following  our  initial  cell  culture
experiments we have identified (among many candidate formulations) a group of liposome
encapsulating TLR ligand formulations behave more active than their free counterparts (as
evidenced by increased cytokine production and message level as well as surface marker
upregulation). In vitro studies although are important, it is not sufficient to deduce that these
novel designs will perform similarly when they are injected in vivo. Among selected CpG
ODN types, and dsRNA ligand, our observations led us to postulate that D-Type ODNs
breadth of activity with or without pIC is more pronounced compared to K-Type CpG ODN
when used within liposomes (increased Type I and Type II interferon, and Th1 biased
cytokine secretions, co-stimulatory molecule and surface marker upregulation).
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The initial experiments were designed to establish in vivo immunostimulatory
potential of various liposomes encapsulating D-Type ODNs (D35 or D3CG) or pIC and their
combinations co-encapsulated within 5 different liposomes.  Mice were injected with
different free or liposomal D35, pIC and combinations of D-ODN+pIC. Following ip
injection  spleens  were  extracted  and  split  into  two  parts.  Half  of  the  spleen  cells  were
incubated ex vivo and assayed for cytokine secretion, the other half was used to extract total
RNA and was studied for i) TLR upregulation, ii) cytokine, chemokine and co-stimulatory
molecule message change by PCR, and iii) co-stimulatory molecule upregulation by FACS.
4.4.1. Immunostimulatory activity of D3CG and pIC coencapsulating liposomes ex
vivo.
To reveal the in vivo activity of various liposomes encapsulating only D-ODN, or
only pIC and coencapsulating D+pIC, mice were ip injected with different nucleic acid-
liposome formulations individually and 4h post injection, spleen cells were removed and
incubated for an addition of 24h in culture (no further stimulation at this stage). Spleen cells
at  the  end  of ex vivo stimulation  were  stained  with  anti-CD86-FITC  antibody  to  detect
CD86+ cells.
The internalization efficiencies of the free vs liposomal formulations vary at great
extend. Following ip injection, amount of free nucleic acids that is draining into spleen is
maximized in 1 hour. Nucleic acids that remained in serum are digested by nucleases and
thus amount of draining nucleic acids fall off sharply. However, the time, when liposomal
nucleic acids draining into spleens get maximized, is later than 4th hour of injection. (Fenske
et al. 2001; Gursel et  al. 2001; Mutwiri et al. 2004). Therefore, extracting spleen of mice
after  4th hour of injection can be considered as terminating the drainage of nucleic acid
encapsulating liposomes prematurely although all of the free nucleic acids, which were not
digested, have already been drained. This attempt is actually a way of favoring free nucleic
acids over their liposomal forms. Moreover we have favored free nucleic acids for the second
time by injecting 2.5 fold more D-ODN (50 μg) as opposed to 20 μg liposomal D-ODN
(same trend was kept for pIC treatments). Overall, all tested liposomal formulations
upregulated CD86. Among D35 group, SSCL-D35 upregulated CD86 at same level
compared to those cells treated with free D35 although 2.5 fold less of CpG was used during
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ip treatment of the animals (Figure 28). For pIC group, free ligand treatment gave 8.6 %
CD86+ cells,  Stealth  liposomal  pIC treatment  led  to  about  14% CD86+ cells  (again  please
note that free ligand is 2.5x more than liposome formulations). When D+pIC co-encapsulated
group is investigated (see right panel of Figure 28), neutral and anionic liposome(D+pIC)
treatments surpassed free D+pIC injected group CD86 upregulation (11.2, 9.2 vs 8.5). Please
note that similar fold difference was kept throughout this group during ip injections.
Additionally, it is very important to note that total amount of activated cells by neutral
liposome encapsulating D35 and pIC is 1.5 and 2 fold more than neutral liposome
encapsulating D35 and pIC alone respectively (please consider bars marked with “*”). Same
trend is valid for anionic liposome encapsulations either (denoted as “¶”). This finding is a
very  clear  demonstration  of  the  augmented  activity  of  D-ODN  and  pIC  when  they  are
coencapsulated in liposomes.
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Figure 28: Percentage of CD86 expressing splenocytes extracted from mice 4 hours later
immunization with 50μg/animal free D35 or pIC, 50μg/animal free D35 and pIC together
(25μg/ml each), various liposome encapsulated 20 μg /animal D35, 20 μg /animal pIC and
various liposome coencapsulated 20 μg/animal ligands (containing D3CG and pIC 10 μg each).
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4.4.2. Effect of ex vivo stimulation with various liposomes encapsulating or
coencapsulating D-ODN and pIC on gene message levels of spleen cells
We have checked cytokine/chemokine and TLR message upregulation levels
following 4h of post ip injection.
PCR  analysis  from  cells  recovered  after in  vivo stimulation with various liposomes
encapsulating or coencapsulating D35 and pIC revealed that independent of the ligand and
liposome type nearly all formulations gave better gene message activity profiles compared to
untreated naive animals, implying that the degree of internalization/uptake (or binding) after
4h of in vivo treatment with these formulations are sufficient enough to trigger an orchestral
cellular activity program. As demonstrated in Figure 29 neutral and anionic liposomes
coencapsulating D3CG and pIC induced higher transcript levels of all investigated
parameters as shown below (please see for more details, Figure 29 right panel). These data
are in good agreement with in vitro ELISA and PCR findings (see Figure 23-Figure 26).
Similarly, pIC encapsulated stealth liposome group reproduced the in vitro observations.
Contrary to our in vitro expectations, however, cationic liposome incorporating pIC did not
induce appreciable degree of most gene message up-regulation (please investigate middle
panel 3rd column in Figure 29, and Figures 30-32).  Out of 11 different genes investigated it
is fair to summarize that stealth liposomal pIC augmented both in vitro and in vivo gene
message levels (please compare Figs. 17-19 and Figs. 29-32 for more details).
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Figure 29: PCR results that were performed from total RNA of splenocytes extracted from mice 4 hours
later immunization with various liposome encapsulated 20μg/animal D35, 20μg/animal pIC and various
liposome coencapsulated 20μg/animal D3CG and pIC (10μg/animal each).
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Figure 30: OD measurement results of the gel electrophoresis picture in Figure 29 for IFNα (a),
IFNγ (b), IL6 (c) and IL18 (d). Density measurement values of genes were normalized according
to β-actin as housekeeping gene by dividing density value of gene to density value of β-actin.
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Figure 31: OD measurement results of the gel electrophoresis picture in Figure 29 for IL15 (a),
TNFα (b), CD40 (c) and IP10 (d). Density measurement values of genes were normalized
according to β-actin as housekeeping gene by dividing density value of gene to density value of
β-actin.
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Figure 32: OD measurement results of the gel electrophoresis picture in Figure 29 for TLR3 (a),
TLR7 (b) and TLR9 (c). Density measurement values of genes were normalized according to β-
actin as housekeeping gene by dividing density value of gene to density value of β-actin.
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4.4.3. In vivo Immunization Studies utilizing liposomal CpG and Ovalbumin
The utmost aim of this thesis was to investigate enhanced immunostimulatory
properties of liposome encapsulating nucleic acid TLR ligands. Following in vitro and ex
vivo analysis one of the most promising formulation was selected and immunization studies
were planned. For this, we have selected ovalbumin (OVA) as a model protein antigen,
which is ‘gold standard’ antigen used extensively during immunization experiments. We
have injected OVA either mixed with free D-ODN or co-encapsulated form with the oligo in
anionic liposomes.
Throughout this study, our findings suggested that the breadth of activation of D
incorporating anionic liposomes performed far better than K-type liposomal preparations and
in many instances gave better response than pIC formulations. Of note, we have not selected
pIC+D combination in liposomes. The major reason for that was the problem associated with
one of the lipid components (PEG2000-DOPE) during stealth liposome generation. We have
yet to understand this issue, since we have no idea why we kept on failing during pIC+CpG
stealth liposome preparation. It could be either due to the lipid component or the association
of pIC together with the D-ODN within the liposome vesicle during the regeneration step and
abolished the vesicular liposome structure entirely. We would also select neutral-D35 or
stealth-pIC formulations either. The surpassing feature of these liposomes over anionic
liposome encapsulating D35 is that neutral-D35 and stealth-pIC can activate more APC.
However we have recognized this after we have already started to conduct immunization
experiment.
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Table  13:  Summary  of  relative  IL6  and  IFNγ secretion  inductions,  IFNα transcript  levels  and
activated APC percentages (CD86+ splenocytes) following stimulation with free or various
liposomes encapsulating D35, pIC and D3CG+pIC at lowest doses.
D35 pIC D3CG + pIC
No Lipo 0 + + IL6 *
+ 0 + IFNγ *
+ + + IFNα §
+ + + CD86 †
Neutral ++++ ++++ ++++ IL6 *
++++ +++ + IFNγ *
++++ ++++ ++++ IFNα §
+++ ++ ++++ CD86 †
Anionic ++++ ++++ ++++ IL6 *
++++ ++++ ++++ IFNγ *
++++ + ++++ IFNα §
++ + ++++ CD86 †
Cationic ++ ++++ ++ IL6 *
+ +++ 0 IFNγ *
++ + 0 IFNα §
+ + ++ CD86 †
Stealth ++++ ++++ N.D IL6 *
+ ++++ N.D IFNγ *
++++ ++++ N.D. IFNα §
+++ ++++ N.D CD86 †
SSCL + +++ + IL6 *
+ + + IFNγ *
+ 0 0 IFNα §
++++ ++ + CD86 †
Comparing ELISA data (*) of IL6 and IFNγ  and PCR data (§) of IFNα : Lowest doses were
considered. If stimulation with free ODN (No Lipo) yielded IFNγ or IL6 response, the amount of
cytokine was marked as “+” and relative cytokine secretion inductions was calculated according
to “No Lipo” group. In this case “No Lipo” is the reference group. If “No Lipo” stimulation did
not yield any IFNγ response, “No Lipo” group was shown as “0”. Then the group that yielded
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lowest amount of IFNγ secretion was denoted as “+” and relative IFNγ secretion inductions were
calculated according to that reference group. 0; no induction, +;  <2 fold induction compared to
reference group, ++;  2-3 fold induction, +++; 3-4 fold induction, ++++; 4< fold induction,
N.D; not determined.
Comparing FACS data (†) of CD86: Data from Figure 28 were considered. As concentrations of
free nucleic acids were 2.5 fold more than their liposomal forms, 2.5 fold less of the % CD86+
splenocyte value upon stimulation with free nucleic acids were marked as “+” and relative APC
activation inductions were calculated according to the value denoted as “+”. 0; no activation,
+;1-2 percent more CD86+ cells, ++; 2-3 percent more CD86+cells,+++; 3-4 percent more
CD86+ cells, ++++; >4 percent more CD86+ cells. N.D; not determined
As mentioned in great details (see Section 3.2.6.2) mice were divided into 5 different
treatment groups.  Following bleedings on day-1, mice were ip immunized the next day (at
d=0) for primary response. On d=13, all animals were again tail bled and mouse sera was
saved for primary anti-OVA Ig detection by ELISA. The next day, booster injections were
carried out. On d=28 mice were first bled and then sacrificed, and spleens were frozen for
later use to study PCR.  The collected mouse primary and secondary sera were subjected to
Anti-OVA IgG, IgG1, IgG2a and IgG2b ELISA following serial titrations. The Table 14,
summarizes anti-ova responses of animals treated with different vaccine formulations. In
conventional vaccinations, it is unlikely to detect any anti-Ag Ig response at the end of
primary immunization. This is even very hard if the vaccine is a simple solution of
Ag+Adjuvant.  Here, (see Table 14A for details) it is clearly demonstrated that our novel
vaccine formulation (Gr#5), that is, OVA Ag and CpG Adjuvant co-encapsulated within a
single liposome vesicle (Anionic Liposomes) induced >150 fold more IgG over free
Ag+CpG group (Gr# 3), and 14x more from Ag+Control ODN (Gr#4). In vaccine trials in
addition to total IgG which is an indication of the generated humoral immunity, it is very
important to mount cell mediated immune response, in which one can understand by
checking  the  level  of  IgG2a  titers.  As  seen  in  Table  14A  the  liposomal  formulation  co-
encapsulating Ag+Adjuvant induced substantially higher IgG2a response at the end of single
vaccine injection. When primary bleeding mouse sera was studied, compared to free
OVA+D-ODN (Gr#3) group, over 30 fold more IgG2a from anionic liposomes co-
encapsulating OVA and D-ODN (Gr#5) group was obtained (14±7 vs 428±50).
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Booster injection is the cardinal phase of any vaccination since it induces both
effector T and memory B cells against vaccine antigen. As seen in Table 14B, a very potent
anti-OVA humoral immunity is initiated at the end of 4 weeks (Gr#5 Table 14B). A very
strong improvement in total IgG (that corresponded to >22 fold more IgG) was achieved
when liposomal formulation is used instead of its free solution counterpart (Gr#5 and Gr#3
titers are 28670 are 1300, respectively). IgG1 anti-OVA titers were also significantly high
with liposome co-encapsulation (more than 26 fold raise between Gr#5 vs Gr#3). IgG2a titers
of animals that was treated with Gr#5 was >13 fold more compared to Gr#3 animals. A
significant and modest Ig titer increase was observed with liposome encapsulating control
ODN+OVA. This is not an unexpected outcome, in the literature there are several reports
suggesting that oligo sequences containing no CpG-motifs can induce a modest immune
activation independent of both TLR9 and CpG motifs. This is primarily due to the backbone
chemistry, here our Control ODN possesses PS-PO mixed backbone and this Ag dependent
Ig response could be initiated due to the presence of phosphorotioate regions expressed on
the control ODN.  Moreover, liposome encapsulation probably contributed to this augment
effect.
Our findings demonstrate that delivery of D-ODN and antigen encapsulated in
anionic liposome induces stronger immune stimulation against the antigen than free D-ODN
can mediate. This knowledge will pave the way to design of novel effective vaccine
adjuvants.
Table 14: Primary and secondary anti-OVA IgG subclass responses of mice immunized with free or
liposome encapsulating Ag and CpG ODN.
A. Primary IgG Levels
Gr # Treatment Groups IgG IgG1 IgG2a IgG2b
1 Untreated 7±4 7±4 7±4 7±4
2 Control ODN+ OVA 7±4 7±4 7±2 7±1
3 D3CG+OVA 28±14 14±7 14±7 7±2
4 Anionic Lipo(Control ODN+OVA) 300±150 35±10 7±2 7±1
5 Anionic Lipo(D3CG+OVA) 4250±1000* 112±12* 428±50 7±1
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B. Secondary IgG Levels
Gr.# Treatment Groups IgG IgG1 IgG2a IgG2b
1 Untreated 7±1 7±2 7±2 7±4
2 Control ODN + OVA 7±2 7±4 7±2 7±1
3 D3CG+OVA 1300±450 828±245 112±12 112±12
4 Anionic Lipo(Control ODN+OVA) 5168±2590* 4355±1430* 448±20* 112±20
5 Anionic Lipo(D3CG+OVA) 28672±5050a** 21600±7150a** 1500±250a* 28±4
Female Balb/c mice (6-8 wks old, 5/group) was immunized with OVA (5 μg/ml) plus control or CpG ODN
(15 μg/ml) (free or liposome encapsulated forms) at day 1 and bleed on d=13 before booster injection.
Two weeks post-booster injection mice were first tail bled and then sacrificed. Sera was titrated and
assayed for anti-OVA IgG subclasses and reported as 1/T for primary and secondary antibody response.
Results (mean titer ± SD) are combination of two independent experiments.
a 0.001<p (Gr#4 vs Gr#5 paired t-test analysis comparison).
*0.01<p (represent the statistical significance of Gr#3  vs Gr#4 or Gr#5 paired t-test analysis
comparison)
** 0.0001<p (Gr#3 vs Gr#4 or Gr#5 paired t-test analysis comparison)
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5. DISCUSSION
This study shows that encapsulating pIC and CpG ODN in liposomes yields
differential immune activation depending on the physicochemical properties of liposome
which is not possible to obtain with free ligand. It is possible to enhance activation of TLR
ligand nucleic acids by liposome encapsulation both in vitro and in vivo. Antigen specific
immune response obtained by triggering immune response with D-ODN can be boosted by
coencapsulation of antigen and D-ODN in anionic liposome. Moreover, coencapsulation
enhances the synergism of pIC and CpG ODN.
Advantages of dehydration-rehydration protocol over Ethanol extraction method
approach and detergent dialysis procedure is high encapsulation ratios and providing
opportunity to handle labile molecules. While the highest encapsulation ratio was
encapsulation of K-ODN in neutral liposome with 67.4%, the highest encapsulation is with
98.7% of D35 in SSCL (Table 7).
ODN  releasing  amounts  of  liposomes  differ  according  to  type  of  the  liposome  and
type of CpG ODN. While 40% of ODN is released from anionic liposome in 8 days and
neutral, anionic and stealth liposomes lose majority of their encapsulated ODNs in 5 months,
positively charged liposomes encapsulating any kind of ODN protects their stability. This is
most probably due to electrostatic interaction between negatively charged ODNs and
positively charged lipids. Exceptionally, D-ODNs and its control I-127 encapsulating
liposomes remained their stability regardless of surface net charge. It is interpreted that
positively charged groups generated after formation of G-tetrads on D-ODN interact with
lipids and thus liposomes encapsulating D-ODNs can remain stable (unpublished data).
Anionic liposome encapsulating D35, which we offer as vaccine adjuvant candidate keeps
82.7% of its content even after 5 months. Long shelf life with minimum cold storage
requirements is preferred for pharmaceutical agents. Therefore we can say that our
formulation can fulfill these requirements of medicine industry.
 1555, a design of K-ODN, induces more IFNγ and IL6 secretion when
encapsulated into positively charged liposomes (cationic, SSCL) compared to negatively
charged (anionic) or neutral liposomes (neutral, stealth). These data are actually confirmation
of previously reported data by Gursel et al.(Gursel et  al. 2001).  Interestingly alternative
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design of K-ODN, K23, behaves differently in liposomes compared to 1555. It induces
higher amount of IFNγ and IL6 secretion in neutral and anionic liposomes but the stimulation
is repressed when it is encapsulated into positively charged liposomes. The characteristic
difference between 1555 and K23 is that K23 contains an extra CpG motif and it is size is
12mer while 1555 is 15mer. It is known that structure of CpG ODNs affect activity (Krieg
2006). Additionally these data speculate that not only the physicochemical properties of
liposomes but also the sequence of CpG ODN has effect on differential cytokine secretion.
 We have revealed out that neutral, stealth and anionic liposomes encapsulating
D35 boost IFNγ secretion compared to free form. Stimulation with lowest dose (0.3μM) of
D35 in neutral, anionic and stealth liposomes augmented IL6 secretion for 4, 5 and 2 folds
respectively compared to free D35. 3μM of free D35 can induce as much IL6 secretion as
0.3μM D35 encapsulated into neutral, anionic and stealth liposomes. Contrast to response of
cells to 1555, stimulation with positively charged liposomes repressed both IFNγ and IL6
secretions. Therefore we can conclude that neutral or anionic liposomes encapsulating D-
ODN can induce high amount of cytokine secretion even in low doses.
One of the possible explanations of the repression of immune activation upon
stimulation with positively charged liposome encapsulating K23 and D35 would be induction
of Th2 type immune response. However we have revealed that this is not the case (data not
shown). Another hypothesis is that positively charged liposomes change the subcellular
localization of CpG ODNs. We have suspected that positively charged liposomes prevents
ODNs to be sequestered in early endosome where D-ODN signaling cascade is initiated.
Cationic and SSCL liposomes carry CpG ODNs directly to late endosome. Since D-ODN is
not active at this site the pronounced IFNγ and IL6 secretion by positively charged liposomes
encapsulating 1555 is significantly higher than the liposomes encapsulating D-ODN.
 Another support to this hypothesis that the positively charged liposomes change
the subcellular localization of CpG ODNs comes from the IFNα transcript levels. It is known
that D35 signals from early endosome and induce IFNα production through MyD88 and
IRF7 in pDCs. We have demonstrated that cationic and SSCL liposomes loaded with D35
does not improve IFNα message compared to free D35 counterpart at 8h of stimulation. As
hypothesized, neutral, anionic and stealth liposomes induced significantly high levels of
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IFNα message. Therefore, results implicated that anionic and stealth liposomes keeps D35 at
an extended period compared to free, or positively charged liposomes in the early endosome
leading to more pronounced IFNα message (please see Figure 15 and Figure 16). To
reproduce this finding an in vivo experiment was designed. Mice were injected with free or
liposome encapsulating D35 and spleens were extracted at 4h post-injection to isolate total
RNA and study gene specific messages by PCR (Figure 29). Please note that there is an
intentional  selection  of  the  dose  of  free  vs  carrier  coupled  D35.  Here,  to  compare  the
potency, free was 2.5 fold more than the injected dose of the Liposomal D35. Another choice
was made for the spleen cell harvest from the animals. Here, we selected 4h again
knowingly, to favor free ODN internalization kinetics over liposomal counterpart. Although
we have expected to observe IFNα transcript after stimulation with neutral, anionic or stealth
encapsulating D35 but not with positively charged liposomes groups, only SSCL-D35 lane
gave a positive band. We have extracted spleen of mice after 4th hour of stimulation.
Accumulation rate of different liposomes to spleen is expected to be different at early time
points whereas, free ODN accumulation is at its highest level. The recovered spleens were
checked to identify which liposomes induced more gene transcript. As expected, K-ODN did
not induce any IFNα message. Although Honda et.al reported that encapsulating K-ODN
within cationic liposomes induced IFNα (Honda et al. 2005), in our assay system we could
not detected any transcript with the liposomal forms of 1555. The discrepancy between these
findings could be due to the type of the mouse strain or the type of the selected K-ODN
sequence. Type I interferons are crucial in regulation of innate and adaptive immune
response and they have important roles in autoimmune diseases (Theofilopoulos et al. 2005).
Therefore controlling type I interferon production is highly important for vaccine designs or
cancer therapies.
      CD40 is a receptor expressed on macrophages and important in activation of
infected macrophages with intracellular pathogens by CD4 T cells expressing CD40 ligand.
CD40 is significantly induced by 1555 alone and 1555 encapsulating anionic and stealth
liposome at first hour of stimulation. Free D35 also induces CD40 expression. Therefore we
can say that K-ODN and D-ODN encapsulation into any of the liposomes do not augment its
expression compared to free form.
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 IL18 is considered as IFNγ-inducing factor. Together with IL12, IL18 induces
high amount of IFNγ expression(Dinarello et  al. 2003). It is an important cytokine in
innate(French et al. 2006; Srinivasan et  al. 2007) and adaptive(Iwai et  al. 2008) immune
regulation. Stimulation with 1555 containing liposomes does not augment IL18 expression
compared to free 1555 at first hour of stimulation. Except the free form, liposomal forms of
D35 do not induce IL18 expression. We can conclude that IFNγ induction by liposomal
forms of either D-ODN or K-ODN is not maintained by increased levels of IL18 production.
 We observe IFNα, CD40 and IL18 induction upon control ODN encapsulating
liposomes. These stimulations are TLR independent because the control ODN do not contain
CpG motif. We speculate that high concentration of control ODN that is internalized into
phagocytic cells together with liposomes trigger TLR independent signaling pathways
through recognition by cytosolic DNA sensors such as DAI (Takaoka et al. 2007) or AIM2
(Hornung et al. 2009).
We have also stimulated cells with liposomes encapsulating pIC. Our data indicates
us that neutral, anionic, cationic and stealth liposomes encapsulating pIC induces high
amount of IFNγ and IL6 secretion even at the suboptimal doses of free pIC stimulation. For
instance 2.5μg/ml of pIC encapsulated in anionic liposome yields 170 fold more IFNγ
secretion than even 22.5μg/ml of free pIC. Among liposome types, only SSCL does not
induce significant amount of IL6 and IFNγ secretion.
We have checked IFNα, CD40 and IL18 mRNA levels after stimulation with free pIC
and its liposome encapsulated forms. When pIC is encapsulated in stealth and neutral
liposomes, IFNα message level is augmented. CD40 levels do not show significant difference
either 1st hour or 8th hour of stimulation. At first hour of stimulation differential IL18 levels
were detected. IL18 transcript level increases after stimulation with neutral and cationic
liposomes encapsulating pIC, however pIC encapsulated in stealth liposome suppresses IL18.
It is known that IFNγ expression is induced by IL18 (Takeda et al. 1998) . We have detected
high amount of IFNγ secretion when cells were exposed to neutral, anionic, cationic and
stealth liposomes encapsulating pIC. Therefore we might speculated that IFNγ secretion upon
stimulation with anionic and stealth liposomes is IL18 independent while neutral and cationic
liposome encapsulating pIC induces IFNγ secretion via IL18.
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Previous  studies  have  shown  that  various  combinations  of  TLR  ligands  show
synergistic effect on cytokine secretion (Whitmore et al. 2004; Napolitani et al. 2005; Warger
et al. 2006; Bohnenkamp et al. 2007; Trinchieri et al. 2007). Combination of synergistic TLR
ligands might have implications on vaccine adjuvant design (Zhu et al. 2008). D-ODN and
pIC, which are both type I IFN inducers, mediates synergism by enhancing TRIF and MyD88
dependent pathways separately, which induces proinflammatory cytokines and type I IFNs.
Activated positive feedback loop of IFNα increase levels of IFNα (Prakash et al. 2005;
Honda et al. 2006). We hypothesized that we can augment synergistic effect of pIC and CpG
ODN and thus cytokine levels by coencapsulating them in liposomes. We have shown that it
is  possible  to  increase  synergistic  IFNγ and  IL6  secretion  of  pIC  and  D-ODN  by
coencapsulating them into neutral and anionic liposomes. Interestingly, positively charged
liposomes suppressed immune activation mediated by pIC and D-ODN. This data speculate
us that TLR3 and TLR9 signaling interfere with each other when they are in positively
charged liposomes. Moreover coencapsulation of pIC and D-ODN in neutral and anionic
liposomes induces IFNα and CD40 mRNA levels at eighth and first hour of stimulation
respectively. There was no significant change in either IL15 or IL18 levels after stimulation
with liposomal forms. IL15 and IL18 have role in activation of NK cells which secretes high
amount of IFNγ upon activation (French et al. 2006). Induction of IFNγ secretion by neutral
and anionic liposomes encapsulating D-ODN and pIC might be IL15, IL18 and maybe NK
cell independent. After an infection, until T cells are primed and differentiated into effector T
cells, NK cells start to secrete IFNγ,  which  suppress  dissemination  of  pathogens  at  early
phases of the infection. After completion of naive T cell priming and differentiation process,
CD4+ T cells dominates IFNγ secretion (Murphy et al. 2008). We speculate that upon
liposomal stimulations, activity of NK cells might not be augmented, however IFNγ secretion
that is mediated by CD4+ T cells might be enhanced.
Stability of liposomes effect has deep impact on their activation capacity. Change in
the physical characteristic of liposomes such as size (due to aggregation or fusion of vesicles)
and release of encapsulated nucleic acid would alter stimulatory effect of its cargo. Besides
phospholipids containing polyunsaturated fatty acids, amino phospholipids and cholesterol
(Chol) can undergo per/auto-oxidation or ester bonds in phospholipids would undergo
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cleavage (Gregoriadis 1992). This is the main reason why we observed unexpected CD86
expression results after in vitro stimulation  of  splenocytes  with  D35  and  pIC
co/encapsulating liposomes (Figure 27).
Ex vivo experiments performed with liposomal D35, pIC and their coencapsulated
form showed augmented immunostimulatory activities of nucleic acids in liposomes.
Although 2.5 fold more free D35 and pIC were injected to mice compared to liposomal forms
with neutral, stealth and SSCL liposomes encapsulating D35 induced either very close or
similar amount of DC activation. Stealth liposome encapsulating pIC, neutral and anionic
liposomes coencapsulating D3CG and pIC exceeded amount of APC activation mediated by
free D3CG and pIC. Gursel et al. demonstrated that when 50μg of free or liposomal 1555
was injected to mice, 10 and 8 fold more 1555 were detected in group of mice’s spleen that
were injected with SSCL encapsulating 1555 than group acquired free 1555 at 2h and 24
hours post-injection (Gursel et  al. 2001). This means that liposomal protection of nucleic
acids from nucleases and opsonization by blood serum proteins increases amount of nucleic
acid taken up by lymphoid organs. This would be the main reason of why liposomal D-ODN
and pIC can yield more activation than free forms although concentration of liposomal forms
are 2.5 fold diluted. Here, it is very important to note that the neutral and anionic D or pIC
induced CD86 positive cells were much lower than the treatment involved coencapsulated
D+pIC counterpart. This finding is a very clear demonstration of the augmentation of
immunostimulatory activities of D-ODN and pIC when they are coencapsulated in
liposomes. Moreover as explained earlier, we have adjusted our experimental set-up in such a
way that free D-ODN possessed an advantage over the liposomal formulations, but as seen in
Figure 28 (right panel) both neutral and anionic liposomes encapsulated D+pIC upregulated
more CD86 compared to mice had free D+pIC mixture. It is fair to suggest that, enhanced
immunostimulatory activity provided by liposomes, in addition to the antigen sparing ability
will offer a powerful system against induction of protective immunity during vaccination
studies.
We have obtained significantly high amount of IgG titers after immunization with
liposome encapsulating antigen and CpG ODN compared to their free forms. That is
probably because APCs can internalize both antigen and CpG ODN together. Therefore they
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can provide 3 signals necessary for naïve T cell activation more efficiently. Actually we are
mimicking a pathogen. Bacteria and viruses are closed compartment with antigens and innate
immune receptor ligands are all together. Pathogens are phagocytosed by APC with its every
component. Liposome encapsulated CpG ODN and antigen can be considered as a very
simple pathogen.
In the literature there are some instances of studies that have used same approach. For
instance Joseph et al. demonstrated that when mice were vaccinated once with liposomes
(DMPC:DMPG mole ratio of 9:1) coencapsulating 25 μg CpG ODN and and 0.5μg influenza
virus subunit hemagglutinin and neuraminidase (HN) antigen, they did not observed any
IgG1 titer and 550 IgG2a titer 21 days post infection (Joseph et al. 2002). We have injected
mice with anionic liposome coencapsulating 7.5μg OVA and 15μg D3CG. 13 days later we
have obtained we have obtained 122 IgG1 titer and 428 IgG2a titer. We have made the Ig
level measurements 8 days before Joseph et al. did, we have detected IgG1 levels and IgG2a
levels  were  close.  Although  amount  of  CpG  ODN  and  antigen  types  and  amounts  are
different, we might speculate that the immune response obtained upon our formulation is
more rapid and stronger.
Gursel et al. immunized mice with SSCL coencapsulating 10 μg 1555 and 2μg OVA.
While previous study demonstrated that total IgG titer reached 19000, the present study
showed 1.5 fold more IgG (a titer of 28672). Collectively, our in vivo experiments
demonstrated that contrary to the established dogma D35 when encapsulated within a proper
liposome, it performs as effective as 1555 (one of the most optimum mouse specific ODN).
In this study we established that different liposomes induced differential innate
immune activation otherwise not possible to obtain with free ligand. Coencapsulation of pIC
and D3CG yields synergistic immune activations both in vitro and ex vivo. Adjuvanticity D-
ODN can be enhanced significantly by coencapsulating D-ODN and antigen in anionic
liposome. The information from this work established an unappreciated feature of liposome-
mediated immune modulation and could be harnessed to design more effective therapeutic
vaccines targeting infectious diseases, cancer or allergy.
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6. FUTURE PERSPECTIVE
This study for the first time established a novel property of D-ODN encapsulating
liposome. In our in vivo experiment, enhanced immunogenicity must be translated into
antigens targeting infectious disease or cancer. Had the researcher found enough time he
would have performed these experiments. Data from ex vivo experiment also provided a very
promising future for liposome coencapsulating TLR3 and TLR9 ligand. It is inevitable to
compare the performance of liposomal D run parallel with D+pIC liposomes to establish the
benefits of including TLR3 ligand in this scenario.
Stealth liposome loaded with D and, pIC gave very promising in vitro and ex vivo
readouts ranging from cytokine production, gene expression amplification as well as surface
marker upregulation. Unfortunately for the reasons we have yet to understand one of the
most important components generating stealth liposome was problematic. We have tried to
resolve this problem by using a new batch at hand and unfortunately we could not solve
reproducible stealth liposome generation problem. Although a significant synergistic immune
activation was obtained when anionic and neutral encapsulating D+pIC was used, our
anticipation is that stealth liposomes loaded with D and pIC would perform as effective as
neutral and anionic and these studies must be performed. All these studies mentioned above
would resolve the best formulation suitable for D and pIC.
Recent literature finding suggested that varying distribution of nucleic acid ligand
subcellular localization may drive differential immune responses. Our findings with regard to
different liposomal/ligand formulations suggest that differential immune activation is
probably mediated by localization of different liposomes within subcellular organelles.
Unfortunately these studies were not completed within the time frame of this thesis. Confocal
studies elaborating on this issue must be carried out in the near future and it is of utmost
importance to demonstrate that different liposomes depending on their physicochemical
feature deliver their cargo to different intracellular vesicles. These sets of studies for the first
time provide an insight on the molecular mechanism of how different liposomes mediate
differential immune activation.
Improved induction of IFNα when certain liposome types were used in stimulation
assays (involved in any of the nucleic acid TLR ligands) is a very critical finding.
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Unfortunately due to the unavailability of either FACS or ELISA reagents we had to rely on
the PCR finding. In the future these reagents must be obtained and the IFNα production
capacity mediated by these formulations must be established (both in vitro and in vivo).
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8. APPENDICES
8.1. Appendix A
Standard Solutions, Buffers, Media
Blocking Buffer (ELISA)
· 500 ml 1x PBS
· 25 grams BSA (5%)
· 250 μl Tween20 (0,025%)
Crystal particles of BSA should be dissolved very well, with magnetic-heating stirrer for
20-30 min. The buffer should be stored at -20°C.
Loading Dye (Agarose gel)
· 0.009 grams Bromophenol blue
· 0.009 grams Xylene cyanol
· 2.8 ml ddH2O
· 1.2 ml 0,5M EDTA
· 11 ml glycerol
After preparing, just vortex it.
PBS (Phosphate Buffered Saline) [10x]
· 80 grams NaCl
· 2 grams KCl
· 8.01 grams Na2HPO4 . 2H2O
· 2 grams KH2PO4
into 1 lt ddH2O
pH= 6.8. For 1xPBS’s pH should be ≈ 7.2-7.4. Should be autoclaved prior to use.
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PBS-BSA-Na-Azide
· 500 ml 1x PBS
· 5g BSA
· 125 mg Na-Azide
TAE (Tris-Acetate-EDTA) [50x]
· 242 grams Tris (C4H11NO3)
· 37.2 grams Tritiplex 3 (EDTA= C10H14N2Na2O2 . 2H2O)
· 57.1 ml Glacial acetic acid
into 1 lt ddH2O
Dissolves in ≈1 day. Should be autoclaved. Diluted to 1X prior to use
T-cell Buffer [ELISA]
· 500 ml 1x PBS
· 25 ml FBS (5%)
· 250 μl Tween20 (0,025%)
The buffer should be stored at -20°C.
Wash Buffer [ELISA]
· 500 ml 10x PBS
· 2.5 ml Tween20
· 4.5 lt dH2O
High Glucose DMEM (Hyclone) and RPMI-1640 (Hyclone)
· 2 %: 10 ml FBS (Oligo FBS = inactivated at 65°C, Regular FBS = inactivated at 55°C )
· 5 % : 25 ml FBS
· 10 % : 50 ml FBS
· 5 ml Penicillin/Streptomycin (50 µg/ml final concentration from 10 mg/ml stock)
· 5 ml HEPES (Biological Industries), (10 mM final concentration from 1M stock )
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· 5 ml Na Pyruvate, (0.11 mg/ml final concentration from 100mM, 11 mg/ml stock)
· 5 ml Non-Essential Amino Acids Solution, (diluted into 1x from 100x concentrate stock)
· 5 ml L-Glutamine, (2 mM final concentration from 200 mM, 29.2 mg/ml stock)
In 500 ml media.
